The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.
Elements of limited time intervals, contributing to particular results or situations.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Tumors or cancer of the PROSTATE.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A cell line derived from cultured tumor cells.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Tumors or cancer of the human BREAST.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Studies in which variables relating to an individual or group of individuals are assessed over a period of time.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Tumors or cancer of the LUNG.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
A malignant epithelial tumor with a glandular organization.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Acquired defect of cellular immunity that occurs naturally in macaques infected with SRV serotypes, experimentally in monkeys inoculated with SRV or MASON-PFIZER MONKEY VIRUS; (MPMV), or in monkeys infected with SIMIAN IMMUNODEFICIENCY VIRUS.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
CCR receptors with specificity for CHEMOKINE CCL3; CHEMOKINE CCL4; and CHEMOKINE CCL5. They are expressed at high levels in T-LYMPHOCYTES; B-LYMPHOCYTES; MACROPHAGES; MAST CELLS; and NK CELLS. The CCR5 receptor is used by the HUMAN IMMUNODEFICIENCY VIRUS to infect cells.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV.
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Persons who have experienced prolonged survival of HIV infection. This includes the full spectrum of untreated, HIV-infected long-term asymptomatics to those with AIDS who have survived due to successful treatment.
Antibodies produced by a single clone of cells.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Tumors or cancer of the SKIN.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Proteins that control the CELL DIVISION CYCLE. This family of proteins includes a wide variety of classes, including CYCLIN-DEPENDENT KINASES, mitogen-activated kinases, CYCLINS, and PHOSPHOPROTEIN PHOSPHATASES as well as their putative substrates such as chromatin-associated proteins, CYTOSKELETAL PROTEINS, and TRANSCRIPTION FACTORS.
Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
The return of a sign, symptom, or disease after a remission.
Tumors or cancer of the LIVER.
A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
Established cell cultures that have the potential to propagate indefinitely.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Phase of the CELL CYCLE following G1 and preceding G2 when the entire DNA content of the nucleus is replicated. It is achieved by bidirectional replication at multiple sites along each chromosome.
Pathological processes of the KIDNEY or its component tissues.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Ribonucleic acid that makes up the genetic material of viruses.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
Tumors or cancers of the KIDNEY.
Tumors or cancer of the URINARY BLADDER.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
The period of the CELL CYCLE preceding DNA REPLICATION in S PHASE. Subphases of G1 include "competence" (to respond to growth factors), G1a (entry into G1), G1b (progression), and G1c (assembly). Progression through the G1 subphases is effected by limiting growth factors, nutrients, or inhibitors.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Tumors or cancer located in bone tissue or specific BONES.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Agents that inhibit PROTEIN KINASES.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
CXCR receptors with specificity for CXCL12 CHEMOKINE. The receptors may play a role in HEMATOPOIESIS regulation and can also function as coreceptors for the HUMAN IMMUNODEFICIENCY VIRUS.
A type of CELL NUCLEUS division by means of which the two daughter nuclei normally receive identical complements of the number of CHROMOSOMES of the somatic cells of the species.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
A group of enzymes that catalyzes the phosphorylation of serine or threonine residues in proteins, with ATP or other nucleotides as phosphate donors.
Short sequences (generally about 10 base pairs) of DNA that are complementary to sequences of messenger RNA and allow reverse transcriptases to start copying the adjacent sequences of mRNA. Primers are used extensively in genetic and molecular biology techniques.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
The giving of drugs, chemicals, or other substances by mouth.
The transmission of infectious disease or pathogens from one generation to another. It includes transmission in utero or intrapartum by exposure to blood and secretions, and postpartum exposure via breastfeeding.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing.
Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules.
Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.
Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Roentgenography of a joint, usually after injection of either positive or negative contrast medium.
Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)
The presence of viruses in the blood.
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
An oxidoreductase that catalyzes the reaction between superoxide anions and hydrogen to yield molecular oxygen and hydrogen peroxide. The enzyme protects the cell against dangerous levels of superoxide. EC
Therapy with two or more separate preparations given for a combined effect.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
DNA present in neoplastic tissue.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Antimetabolites that are useful in cancer chemotherapy.

Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status. (1/26795)

AIMS: To correlate vascular endothelial growth factor (VEGF) expression in oral squamous cell carcinoma with the clinicopathological characteristics and prognosis; and to assess whether p53 gene status is associated with VEGF expression in human cancers. METHODS: Tumour specimens from 45 patients with oral squamous cell carcinomas were examined. Expression of VEGF was determined using an immunohistochemical method, and a tumour was considered positive when more than 5% of the neoplastic cells showed VEGF immunoreactivity. The p53 gene status was screened using a polymerase chain reaction--single strand conformation polymorphism analysis. RESULTS: VEGF positive staining was detected in 19 (42.2%) of the 45 cases. VEGF immunoreactivity did not correlate with the histological degree of tumour differentiation, clinical stages, or lymph node metastasis. The patients with VEGF positive tumours had a significantly worse prognosis than those with VEGF negative tumours. The five year overall survival rate of the VEGF negative patients was 76.5%, as compared with 48.8% for the VEGF positive patients. No significant association between VEGF expression and the p53 gene status of the tumours was found. CONCLUSIONS: VEGF is a good prognostic indicator of the survival of patients with oral squamous cell carcinoma. The p53 gene status does not seem to be associated with VEGF expression in these cancers.  (+info)

Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. (2/26795)

Human melanoma cell lines derived from early stage primary tumors are particularly sensitive to growth arrest induced by interleukin-6 (IL-6). This response is lost in cell lines derived from advanced lesions, a phenomenon which may contribute to tumor aggressiveness. We sought to determine whether resistance to growth inhibition by IL-6 can be explained by oncogenic alterations in cell cycle regulators or relevant components of intracellular signaling. Our results show that IL-6 treatment of early stage melanoma cell lines caused G1 arrest, which could not be explained by changes in levels of G1 cyclins (D1, E), cdks (cdk4, cdk2) or by loss of cyclin/cdk complex formation. Instead, IL-6 caused a marked induction of the cdk inhibitor p21WAF1/CIP1 in three different IL-6 sensitive cell lines, two of which also showed a marked accumulation of the cdk inhibitor p27Kip1. In contrast, IL-6 failed to induce p21WAF1/CIP1 transcript and did not increase p21WAF1/CIP1 or p27kip1 proteins in any of the resistant lines. In fact, of five IL-6 resistant cell lines, only two expressed detectable levels of p21WAF1/CIP1 mRNA and protein, while in three other lines, p21WAF1/CIP1 was undetectable. IL-6 dependent upregulation of p21WAF1/CIP1 was associated with binding of both STAT3 and STAT1 to the p21WAF1/CIP1 promoter. Surprisingly, however, IL-6 stimulated STAT binding to this promoter in both sensitive and resistant cell lines (with one exception), suggesting that gross deregulation of this event is not the unifying cause of the defect in p21WAF1/CIP1 induction in IL-6 resistant cells. In somatic cell hybrids of IL-6 sensitive and resistant cell lines, the resistant phenotype was dominant and IL-6 failed to induce p21WAF1/CIP1. Thus, our results suggest that in early stage human melanoma cells, IL-6 induced growth inhibition involves induction of p21WAF1/CIP1 which is lost in the course of tumor progression presumably as a result of a dominant oncogenic event.  (+info)

Economic consequences of the progression of rheumatoid arthritis in Sweden. (3/26795)

OBJECTIVE: To develop a simulation model for analysis of the cost-effectiveness of treatments that affect the progression of rheumatoid arthritis (RA). METHODS: The Markov model was developed on the basis of a Swedish cohort of 116 patients with early RA who were followed up for 5 years. The majority of patients had American College of Rheumatology (ACR) functional class II disease, and Markov states indicating disease severity were defined based on Health Assessment Questionnaire (HAQ) scores. Costs were calculated from data on resource utilization and patients' work capacity. Utilities (preference weights for health states) were assessed using the EQ-5D (EuroQol) questionnaire. Hypothetical treatment interventions were simulated to illustrate the model. RESULTS: The cohort distribution among the 6 Markov states clearly showed the progression of the disease over 5 years of followup. Costs increased with increasing severity of the Markov states, and total costs over 5 years were higher for patients who were in more severe Markov states at diagnosis. Utilities correlated well with the Markov states, and the EQ-5D was able to discriminate between patients with different HAQ scores within ACR functional class II. CONCLUSION: The Markov model was able to assess disease progression and costs in RA. The model can therefore be a useful tool in calculating the cost-effectiveness of different interventions aimed at changing the progression of the disease.  (+info)

Inflammatory cell-mediated tumour progression and minisatellite mutation correlate with the decrease of antioxidative enzymes in murine fibrosarcoma cells. (4/26795)

We isolated six clones of weakly tumorigenic fibrosarcoma (QR) from the tumorigenic clone BMT-11 cl-9. The QR clones were unable to grow in normal C57BL/6 mice when injected s.c. (1x10(5) cells). However, they formed aggressive tumours upon co-implantation with a 'foreign body', i.e. a gelatin sponge, and the rate of tumour take ranged from 8% to 58% among QR clones. The enhanced tumorigenicity was due to host cell-mediated reaction to the gelatin sponge (inflammation). Immunoblot analysis and enzyme activity assay revealed a significant inverse correlation between the frequencies of tumour formation by QR clones and the levels of manganese superoxide dismutase (Mn-SOD, P<0.005) and glutathione peroxidase (GPchi, P<0.01) in the respective tumour clones. Electron spin resonance (ESR) revealed that superoxide-scavenging ability of cell lysates of the QR clone with high level of Mn-SOD was significantly higher than that with low level of the antioxidative enzyme in the presence of potassium cyanide, an inhibitor for copper-zinc superoxide dismutase (CuZn-SOD) (P<0.001). Minisatellite mutation (MSM) induced by the inflammatory cells in tumour cells were investigated by DNA fingerprint analysis after QR clones had been co-cultured with gelatin-sponge-reactive cells. The MSM rate was significantly higher in the subclones with low levels of Mn-SOD and GPchi (P<0.05) than in the subclones with high levels of both enzymes. The MSM of the subclones with low levels of both enzymes was inhibited in the presence of mannitol, a hydroxyl radical scavenger. The content of 8-hydroxydeoxyguanosine (8-OHdG) by which the cellular DNA damage caused by active oxygen species can be assessed was significantly low in the tumours arising from the QR clone with high levels of Mn-SOD and GPchi even if the clone had been co-implanted with gelatin sponge, compared with the arising tumour from the QR clone with low levels of those antioxidative enzymes (P<0.001). In contrast, CuZn-SOD and catalase levels in the six QR clones did not have any correlation with tumour progression parameters. These results suggest that tumour progression is accelerated by inflammation-induced active oxygen species particularly accompanied with declined levels of intracellular antioxidative enzymes in tumour cells.  (+info)

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. (5/26795)

Immunohistochemical, cytochemical and ultrastructural data showing vivid angiogenesis and numerous mast cells (MCs) in the bone marrow of 24 patients with active multiple myeloma (MM) compared with 34 patients with non-active MM and 22 patients with monoclonal gammopathy of undetermined significance (MGUS) led us to hypothesize that angiogenesis parallels progression of MM, and that MCs participate in its induction via angiogenic factors in their secretory granules.  (+info)

Second-line treatment for primary central nervous system lymphoma. (6/26795)

Failure after first-line treatment was reported in 35-60% of immunocompetent patients with primary central nervous system lymphoma (PCNSL). There are currently no reports focusing on salvage therapy. This review analyses prognostic factors and the efficacy of salvage therapy by focusing on data from papers reporting results of first-line treatment in 355 cases. The study group consisted of 173 patients presenting treatment failure. The interval between failure and death (TTD) was compared for age at relapse (< or =60 vs. >60 years), type of failure (relapse vs. progression), time to relapse (< or =12 vs. >12 months) and salvage treatment (yes vs no). Median TTD was similar in younger and older patients (P = 0.09). Relapsed patients had a longer TTD than patients with progressive disease (P = 0.002). Early relapse led to a shorter TTD than late relapse (P = 0.005). Median TTD was 14 months for patients who underwent salvage therapy and 2 months for untreated cases (P<0.00001). A multivariate analysis showed an independent prognostic role for salvage therapy and time to relapse. Age and type of failure had no predictive value. Salvage therapy significantly improves outcome and, possibly, quality of life. As many different treatments were used conclusions cannot be made regarding an optimal treatment schedule.  (+info)

Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer. (7/26795)

Total cytosolic cathepsin D (Cat D) levels were estimated by an immunoradiometric assay in a series of 156 consecutive patients with surgical stages I-III primary endometrial adenocarcinoma. Simultaneously, the tissue content of both oestrogen (ER) and progesterone (PR) receptors, and p185HER-2/neu, DNA content (ploidy), and the fraction of S-phase cells (S-phase) were also estimated. Tumoral Cat D content ranged from 0 to 243 pmol mg(-1) protein (median 44 pmol mg(-1) protein) and was not associated with any of the established clinicopathological and biological prognostic variables, with the exception of a weak positive correlation with the tumoral p185HER-2/neu levels. Univariable analysis performed on a subset of 97 patients, followed for a minimum of 2 years or until death, showed that patient age at diagnosis, high histological grade, advanced surgical stage, vascular invasion, positive peritoneal cytology, low levels of Cat D, negative ER and PR status, aneuploidy, and high S-phase were predictive of the presence of persistent or recurrent disease. However, multivariable analysis revealed that only histological grade, surgical stage, Cat D and PR were significantly associated with the patient's outcome. From these findings, we conclude that Cat D is an independent prognostic factor in endometrial adenocarcinoma, its low levels being associated with a worse clinical outcome.  (+info)

A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. (8/26795)

To investigate involvement of an aberrant expression of the FHIT (fragile histidine triad) gene in the process of carcinogenesis and progression in cervical carcinoma, we examined its expression by the reverse transcriptase polymerase chain reaction (RT-PCR) and cDNA sequence method in 32 cervical invasive carcinomas (25 squamous cell carcinomas and seven adeno- or adenosquamous carcinomas) and 18 of its precursor lesions [four low-grade and 14 high-grade cervical intraepithelial neoplasias (CINs)]. We also examined a link between the occurrence of the aberrant expression and human papillomavirus (HPV). We detected the aberrant FHIT transcripts in 11 of 25 (44%) cervical invasive squamous cell carcinomas and in 5 of 14 (36%) high-grade CINs (CIN 2 or 3), whereas they were not found in seven non-squamous type and four low-grade CINs (CIN 1). The alteration patterns of the FHIT gene expression in high-grade CINs were virtually similar to those found in invasive carcinomas, such that the exons 5-7 were consistently deleted associated or unassociated with loss of the exon 4 and/or 8. The incidence of the aberrant expression was not related to the presence of HPV and its type. These data indicate that the aberrant expression of the FHIT gene is observed in precursor lesions of cervical carcinoma as well as invasive carcinomas, with its incidence not increasing with advance of clinical stage. Given the squamous cell type dominant expression, the aberrant expression may play a critical role in the generation of squamous cell carcinoma of the uterine cervix, but not the consequence of the progression of the cancer.  (+info)

TY - JOUR. T1 - CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. AU - Beers, David R.. AU - Henkel, Jenny S.. AU - Zhao, Weihua. AU - Wang, Jinghong. AU - Appel, Stanley H.. PY - 2008/10/7. Y1 - 2008/10/7. N2 - Neuroinflammation, marked by gliosis and infiltrating T cells, is a prominent pathological feature in diverse models of dominantly inherited neurodegenerative diseases. Recent evidence derived from transgenic mice ubiquitously overexpressing mutant Cu2+/Zn2+ superoxide dismutase (mSOD1), a chronic neurodegenerative model of inherited amyotrophic lateral sclerosis (ALS), indicates that glia with either a lack of or reduction in mSOD1 expression enhance motoneuron protection and slow disease progression. However, the contribution of T cells that are present at sites of motoneuron injury in mSOD1 transgenic mice is not known. Here we show that when mSOD1 mice were bred with mice lacking functional T cells ...
Chronic kidney disease (CKD) affects 13.6% of the adult population of the United States, with a projected increase to 16.7% expected by 2030.1,2 Risk factors for progression of CKD include diabetes, albuminuria, and various cardiovascular comorbidities, which provide the targets for current CKD management.3-6 Adverse cardiovascular events and mortality increase with CKD progression.7-11 The associations between decreased estimated glomerular filtration rate (eGFR) and risk for major cardiovascular events and death appear independent of concomitant chronic diseases (eg, cardiovascular disease or heart failure).7. Prevalence estimates of CKD, based on cross-sectional analyses,12,13 provide a snapshot with little information about CKD progression over time. Most information on effects of CKD progression on health care costs were also derived from cross-sectional studies. Notwithstanding these limitations, a direct association between progression and cost was demonstrated in Australia, where annual ...
Supplementary Material for: Association Between Chronic Kidney Disease Progression and Cardiovascular Disease: Results from the CRIC Study
Specific regions of the vascular tree are more susceptible to the development of atherosclerosis than others, and these regions are found to have abundant SMCs in the intima. In vitro mechanistic and in vivo correlative data provide evidence that these phenotypically modulated SMCs participate in functions that can lead to atherogenesis as outlined above. While these data suggest a key role for SMCs in the initiation and early progression of atherosclerosis, mechanistic in vivo data confirming the role of SMCs in these processes are just recently surfacing. These studies have been hindered by the fact that lesions are complex and many SMC functions that would lead to atherosclerosis initiation and progression are redundant with other cell types that participate in early lesion development. More definitive studies involving the depletion of a specific cell type, as has been done with specific inflammatory cell populations to confirm their role in atherosclerosis, are not feasible for SMCs because ...
Barbara London: Natural Progression jazz review by Jim Santella, published on November 24, 2004. Find thousands reviews at All About Jazz!
This axis is devoted to the study of biological and toxicological effects of chemical contaminants in the context of populations considered at risk for the genesis of severe liver disease. Thus, the goal of this axis is to determine if environmental contaminants could play a role in the pathologic progression of steatosis using in vitro and in vivo models. In addition, another population at risk is targeted: alcohol consumers, considering this lifestyle factor as an important and well-known hepatic toxicant.. Membrane remodeling and signaling are studied following treatment with PAHs or phthalates in combination or not with ethanol or dietary lipids. Both in vitro (rodent or human cell lines: hepatocytes, endothelial cells, blood cells) and in vivo models (Zebrafish larvae) are used. A special focus is brought to the impact of pollutant exposure on the disease progression of liver steatosis (ANR CESA STEATOX project). Various factors involved in membrane remodeling (reactive metabolites, ...
Here we evaluated the performance of a large set of serum biomarkers for the prediction of rapid progression of chronic kidney disease (CKD) in patients with type 2 diabetes. We used a case-control design nested within a prospective cohort of patients with baseline eGFR 30-60 ml/min per 1.73 m(2). W …
Results: Two hundred and fifty three adolescents with pre-endstage CKD were seen during this period. The main primary diseases were glomerulopathies (35.2%) and congenital anomalies of the kidney and urinary tract (28.9%). The majority were at CKD Stage 1 (53.3%) or 2 (26.5%) at baseline. Thirteen patients (9.3%) reached the composite outcome. Forty-two patients (30.0%) progressed by at least one CKD stage. Twenty-two of these 42 patients (52.4%) were at milder stages of CKD (Stage 1 or 2) at baseline. In univariate analysis, significant predictors of progression to the composite endpoint included CKD Stage 3 or 4 at entry (p=0.02), severe proteinuria (p=0.018), short stature (p=0.047), anaemia (p=0.07), hypoalbuminemia (p,0.005) and hyperphosphatemia (p,0.005). In the multivariate model, CKD Stage 3 or 4 (OR 5.11, 95% CI 1.15-22.60; p=0.032) and severe proteinuria (OR 9.19, 95% CI 1.26-67.16; p=0.029) were independent predictors ...
Objective. To assess clinical progression and inflammatory markers among women stopping or continuing antiretroviral therapy (ART) after pregnancy. Methods. ART-naïve women with CD4+ lymphocyte counts ,350 cells/uL initiating ART during pregnancy had clinical events and laboratory markers compared over one year postpartum between those stopping (n = 59) or continuing (n = 147) ART. Results. Slopes in CD4 count and HIV RNA did not differ between groups overall and in subsets of ZDV or combination therapy. The hazard ratio (HR) of a new class B event was 2.09 (95% CI 0.79-5.58) among women stopping ART, 1.24 (0.31-4.95) in those stopping ZDV, and 2.93 (0.64-13.36) among those stopping combination therapy. Women stopping ART had increased immune activation. No significant differences were seen in C-reactive protein, lipids, leptin, or interleukin-6. Conclusions. While changes in CD4 and HIV RNA levels over one year were similar between women stopping or continuing ART postpartum, higher immune ...
Drug-eluting stents (DES) implantation has been demonstrated to dramatically reduce restenosis and repeat revascularisation (RR) in diabetic patients. However, diabetic patients are prone to an accelerated atherosclerotic process and the impact of atherosclerotic disease progression (ADP) on RR and mid-term clinical outcome after DES implantation is not well known To determine whether RR in diabetic patients treated with prior DES is the result of either DES restenosis or native progression of atherosclerotic disease in the coronary vasculature, and to evaluate the impact of ADP on the mid-term clinical outcome. We followed 316 consecutive diabetic patients (227 men, age 69 ± 9 years) treated between June 2005 and September 2006 with at least one DES. Of these patients, 260 (82%) had a multivessel coronary disease, 148 (41%) had previous coronary revascularisation and 104 (32%) had insulin-dependent diabetes. During the follow-up (mean 590 ± 194 days) the cumulative incidence of major adverse ...
Author Summary In recent decades, our understanding of Alzheimers disease (AD) has increased; however, some basic questions still remain unresolved. One of them is: how homogeneous is AD? Is the course of progression more or less the same for most patients, or are there large variations? Our paper studies a large cohort of AD patients which comes from a 23-year-long study, and performs a statistical analysis of progression speed. We quantify the amount of spread in GDS/FAST stage durations (a staging system widely used by clinicians). We arrive at an astonishing conclusion that the mean length of AD stages is comparable with their standard deviation! This means that individual courses of AD progression may differ very much from each other, and from the textbook mean values. This has implications both for clinical trials (how do we assess if a new drug is effective, if the amount of natural spread is so large in untreated patients?), and for our understanding of this disease, which appears to be
The investigators propose to conduct a retrospective study of single agent ceritinib in patients with previously untreated anaplastic lymphoma kinase (ALK)
An interesting paper in Anaesthesiology, (and yes, I know its not top of everyones reading list), looks at the influence of the mu opiod receptor (MOR) on cancer progression. While you may not have heard of the MOR, you will have heard of the drugs that target this receptor: morphine, fentanyl, heroin and other opiates. These are among the most widely used of pain-relief drugs in current medical practice. In particular these drugs are widely prescribed for cancer patients, either when undergoing surgery or when they are suffering from pain. The question of whether these drugs have an effect on cancer progression is one that is directly relevant to cancer patients here and now. While it has been known for some time that opiate drugs possibly have some indirect effects on disease progression because of the depressive effect on the immune system, the authors of this paper take things a step further and ask whether there is also a direct pro-tumour effect induced by these opiates ...
In the UK, our center and others screen for KRAS routinely-but without any purpose really. Id like to think that, based on this evidence, this will be a new stratified treatment option for us, Dr. Fennell added.. About CodeBreak 100. The global open-label phase I/II CodeBreak 100 trial evaluated sotorasib administered orally at 960 mg/d to 126 patients with advanced NSCLC and a centrally confirmed KRAS p.G12C mutation. Patients had experienced disease progression after up to three lines of therapy, including platinum-based chemotherapy and/or agents targeting PD-1/PD-L1. More than 80% of patients had experienced disease progression on both chemotherapy and PD-1/PD-L1 inhibitors.. The primary endpoint was objective response by blinded independent central radiology review. Patients were followed for a median of 12.2 months.. Key Outcomes and Toxicity. Of 124 evaluable patients, 46 patients (37.1%) had a confirmed response, including 3 patients with a complete response; disease control was ...
TY - GEN. T1 - A mechanism-based disease progression model to analyse long-term treatment effects on disease processes underlying type 2 diabetes. AU - Rozendaal, Y.J.W.. PY - 2013. Y1 - 2013. M3 - Conference contribution. BT - Eindhoven Metabolic Syndrome Workshop: Modeling the interplay of fat and carbohydrate metabolism with application in Metabolic Syndrome and Type 2 Diabetes. CY - Eindhoven. ER - ...
The value of HIV-RNA quantification as a prognostic marker has long been established [6, 51, 52]. An approximately inverse relationship to the CD4+ T-cell count and survival time has been observed in around 80% of patients [53, 54]. Higher HIV-RNA levels are associated with more rapid decline of CD4+ T-cells, assisting prediction of the rate of CD4 count decline and disease progression. However, once the CD4 count is very low (,50-100 cells/mm3), the disease progression risk is so great that HIV-RNA levels add little prognostic information [25, 54-56]. The correlation between CD4 count and disease progression seen clearly in Table 1 has already been described [10]. Further highlighting the risk of AIDS in those with CD4 counts of 200-350 cell/mm3 (the current threshold for ART initiation), a four-fold risk increase can be seen between those with a HIV-RNA of 3000 copies/mL and those with ≥300 000 copies/mL, even within the same age bracket. Additionally, there is a considerable increase in ...
The University of California, San Diego School of Medicine is one of 18 official study sites for the Parkinsons Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinsons disease (PD) progression. Enrollment of 20 patients and 10 controls is expected to continue for approximately two years.
A family history of prostate cancer was not a major determinant of disease progression during active surveillance, according to a systematic review.
DESIGN/METHODS:We evaluated 369 drug-naïve ePD patients. Data were obtained from the Parkinson?s Progression Markers Initiative (PPMI) database. CSF amyloid-beta levels were transformed using a previously reported linear regression procedure. A cutoff of >198 pg/mL was used to define amyloid-negative (PD-) and amyloid-positive (PD+) subgroups. Grey matter (GM) density from MRI was measured using ANTs. We compared groups using linear regressions ...
THE PARKINSON S PROGRESSION MARKERS INITIATIVE (PPMI) is a landmark study launched in 2010 to find biomarkers disease indicators that are critical missing links in the search for better Parkinson s disease (PD) treatments.
4D pharma Joins Landmark Parkinson’s Progression Markers Initiative A landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson’s disease and accelerate the development of new treatments 4D pharma will play an important role as PPMI considers the microbiome as an...
In the MESA, persons with MetS or DM have a greater incidence and progression of CAC than those subjects without MetS, and those with MetS (without DM) have an intermediate incidence and progression. Also, insulin resistance (23) and DM (24,25) have been shown in smaller or selected cohorts to relate to progression of CAC, and in those with DM, a glycated hemoglobin ≥7% predicted progression of CAC (26). Progression of CAC has also been shown to predict total mortality over baseline risk factors and CAC (13). In our study, we also found increased progression of CAC in persons with MetS and DM to predict future CHD events.. The baseline calcium score, a strong predictor of CAC progression, is important to understanding the relationship of MetS and DM to progression of CAC (23,27). Because MetS is associated with an intermediate level and DM the highest level of CAC, we might expect a similar pattern for progression. Whereas baseline CAC could be considered a confounder, it can also be ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Recent studies suggest that risk of Alzheimers disease can be dramatically reduced by following health diet and lifestyle. Although the exact cause of
TY - JOUR. T1 - Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome. T2 - The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. AU - The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. AU - Maccari, Maria Elena. AU - Abolhassani, Hassan. AU - Aghamohammadi, Asghar. AU - Aiuti, Alessandro. AU - Aleinikova, Olga. AU - Bangs, Catherine. AU - Baris, Safa. AU - Barzaghi, Federica. AU - Baxendale, Helen. AU - Buckland, Matthew. AU - Burns, Siobhan O. AU - Cancrini, Caterina. AU - Cant, Andrew. AU - Cathébras, Pascal. AU - Cavazzana, Marina. AU - Chandra, Anita. AU - Conti, Francesca. AU - Coulter, Tanya. AU - Devlin, Lisa A. AU - Edgar, J David M. AU - Faust, Saul. AU - Fischer, Alain. AU - Garcia-Prat, Marina. AU - Hammarström, Lennart. AU - Heeg, Maximilian. AU - Jolles, Stephen. AU - Karakoc-Aydiner, Elif. AU - Kindle, Gerhard. AU - Kiykim, Ayca. AU - ...
For the first time, researchers have determined how toxic tau fibrils spread by the help of brain immune cells called microglia during the early stages of Alzheimers disease (AD). The discovery of this new pathway may lead ...
In this study, we aimed to characterise rapid progressors to type 1 diabetes among children recruited from the general population, on the basis of HLA-conferred disease susceptibility. We monitored 74
Among the 75,335 included participants, the progression rate to hypertension was 66.39% (50,013), with an adjusted incidence rate of 8.62 per 100 person-year in the aged 40-64 group and 12.68 in the aged 65 or above group. Age, BMI, hemoglobin, and family history of hypertension and other diseases were related to the progression. Among the progression group, 78.21% (39,116) participants skipped a pre-hypertensive status; this group consisted of older females with lower pulse pressure and more alcohol consumption compared to people who had pre-hypertensive status before the progression ...
Age is the greatest risk factor for the development of epithelial cancers. In this minireview, we will examine key extracellular matrix and matricellular components, their changes with aging, and discuss how these alterations might influence the subsequent progression of cancer in the aged host. Because of the tight correlation between advanced age and the prevalence of prostate cancer, we will use prostate cancer as the model throughout this minireview. ...
According to results from the phase III CHRONOS-3 trial, patients with relapsed indolent non-Hodgkin lymphoma may benefit significantly from the addition of copanlisib, a pan-PI3K inhibitor, to standard rituximab. The combination was safe and nearly halved the risk of disease progression or death, compared with placebo and rituximab. ...
An alcoholic or addict in the lasts might be destitute, exceptionally ill, psychologically confused, and drinking or usage drugs practically constantly. The alcoholic or addict in this stage is suffering from numerous physical and mental problems due to the damage to vital organs. His or her immunity to infections is reduced, and the employees mental condition is really unstable. Some of the really serious medical conditions the alcoholic or addict faces at this moment consist of cardiac arrest, fatty liver, hepatitis, cirrhosis of the liver, lack of nutrition, pancreatitis, breathing infections, and mental retardation, a few of which is reversible ...
Alzheimer Alzheimers Disease Progression English Edition can be very useful guide, and Alzheimer Alzheimers Disease Progression English Edition play an important role in your products. The problem is that once you have gotten your nifty new product, the Alzheimer Alzheimers Disease Progression English Edition gets a brief glance, maybe a once over, but it often tends to get discarded or lost with the original packaging. ...
Horses - The New Other White Meat?. Ive never understood the U.S. prohibition on slaughtering horses for human consumption. As an observant Jew, horses arent kosher. So, Id never eat them even if I could. Still, while the thought of eating horses disgusts me-I love horseback riding and, because of that, have an affinity for the animal-why are horses any more special than any other animal we slaughter and eat?. Is horsemeat any less healthy than a steak or chicken? Not being a nutritionist or dietitian, I have no idea. Id never eat dog or cat or snake (and none of those are kosher, so even if I wanted to, my religion prohibits it). But if you believe-as I do-that animals are here to serve man, that we can ride them, eat them, and use them for leather, fur, and feathers, then why are horses any more sacred than other living beings to which we do these things and gain these materials for our use?. They arent . . . unless youre a PETA (or as I call it, PUTAh-People for the Unethical ...
OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups according to timing of disease progression while enrolled on protocol FAV-ID-06 (disease progression after prior rituximab AND never randomized vs disease progression after randomization to placebo arm).. Patients receive autologous immunoglobulin idiotype-KLH vaccine subcutaneously (SC) on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4. Treatment repeats monthly for 6 months in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive additional treatment as above every 2 months for 1 year (6 treatments) and every 3 months until disease progression.. After completion of study treatment, patients are followed for 30 days or until the start of subsequent treatment.. PROJECTED ACCRUAL: Approximately 238 patients (67 in group I and 171 in group II) will be accrued for this study.. ...
The FDA approved abemaciclib (Verzenio) for use in combination with fulvestrant in women with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy. The CDK4/6 inhibitor has also been approved as a monotherapy for patients with HR+/HER2- breast cancer with metastatic disease who have previously received endocrine therapy and chemotherapy.
Abemaciclib (Verzenio) has been approved by the FDA for use as a monotherapy and in a combination regimen for patients with HR-positive/HER2-negative breast cancer. As a monotherapy, the CDK4/6 inhibitor has been approved for patients with metastatic disease who have previously received endocrine therapy and chemotherapy, and as a combination, abemaciclib has been approved for use with fulvestrant for women with advanced breast cancer with disease progression following endocrine therapy.
As new, personalized treatments are developed to slow disease progression, there is a vital need for imaging methods that can detect response to therapy at early follow-up times.
in PLoS ONE (2011), 6(11), 26450. Meprin-α is a metalloprotease overexpressed in cancer cells, leading to the accumulation of this protease in a subset of colorectal tumors. The impact of increased meprin-α levels on tumor progression is ... [more ▼]. Meprin-α is a metalloprotease overexpressed in cancer cells, leading to the accumulation of this protease in a subset of colorectal tumors. The impact of increased meprin-α levels on tumor progression is not known. We investigated the effect of this protease on cell migration and angiogenesis in vitro and studied the expression of meprin-α mRNA, protein and proteolytic activity in primary tumors at progressive stages and in liver metastases of patients with colorectal cancer, as well as inhibitory activity towards meprin-α in sera of cancer patient as compared to healthy controls. We found that the hepatocyte growth factor (HGF)- induced migratory response of meprin-transfected epithelial cells was increased compared to wild-type cells in ...
The therapeutic goals for Pulmonary Arterial Hypertension are to improve the hemodynamic parameters, delay disease progression, improving quality of life and exercise tolerance, and minimizing mortality risks. This activity will focus on several important aspects of PAH management including a review of the predictors of disease progression and clinical outcomes of PAH; the current data on the use of NYHA functional class as a predictor of future survival and disease progression; a discussion of the clinical trial data on existing and emerging therapeutics for the management of PAH; and a review of effective strategies to tailor therapeutic regimens and improve clinical outcomes in patients with PAH ...
The identification of clinical risk factors for AIDS in patients with preserved immune function is of significant interest. We examined whether patients with fungal infection (FI) and CD4 cell count ,/=200/microl were at higher risk of disease progression in the era of cART. 11,009 EuroSIDA patients were followed from their first CD4 cell count ,/=200/microl after 1 January 1997 until progression to any non-azoles/amphotericin B susceptible (AAS) AIDS disease, last visit or death. Initiation of antimycotic therapy (AMT) was used as a marker of FI and was modelled as a time-updated covariate using Poisson regression. After adjustment for current CD4 cell count, HIV-RNA, starting cART and diagnosis of AAS-AIDS, AMT was significantly associated with an increased incidence of non-AAS-AIDS (IRR=1.55, 95% CI 1.17-2.06, p=0.0024). Despite low incidence of AIDS in the cART era, FI in patients with a CD4 cell count ,/=200/microl is associated with a 55% higher risk of non-AAS-AIDS (95% confidence ...
The duration of the study for the patients will include a period for screening of up to 3 weeks. Patients will continue study treatment until disease progression, unacceptable adverse reaction, patients wish or other reason of discontinuation. During follow-up, patients who discontinue the study treatment due to progression of the disease will be followed every 3 months (12 weeks) for further anti-myeloma therapies, progression free survival to the second progression and survival, until death or the cut-off date, whichever comes first. Patients who discontinue the study treatment prior to documentation of disease progression will be followed-up every 4 weeks until confirmation of disease progression, and then every 3 months (12 weeks) for further anti-myeloma therapies, progression free survival to the second progression and survival, until death or the cut-off date, whichever comes first. After progression free survival analysis, patients will be followed yearly for 3 years for survival ...
For Plato, governments seem to have a natural progression. A just city will begin by establishing an aristocracy to guide itself toward the good. As those leaders lose sight of the good, focusing on their own power and desires, the aristocracy will rot into a timocracy, an oligarchy, and so on. It is almost inevitable that this occur. Once a tyranny is established, the next step is back to an aristocracy or otherwise just form of government. This can only occur when one who has experienced the good is willing to return to the cave as it were (an analogy Plato uses in Book VII) and direct the city. An instance of this occuring will be discussed. This progression can be applied to the process all energy on Earth goes through. It is all derived from the nuclear fusion occuring on the sun that makes it into our atmosphere. As energy is used and changed, it is transferred into different forms that are not as easily utilized. One could say that it is being corrupted. As energy is transferred throuugh ...
Analysis of gene expression in tissues affected by ANCA vasculitis provides new insight into the mechanisms involved in disease progression, a study finds.
The CREDENCE trial [3] provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria. The Phase III DAPA-CKD trial [1] has now shown that the SGLT2 inhibitor Dapagliflozin can significantly slow CKD progression in all CKD patients, not only in those with diabetes. This breakthrough in kidney disease treatment goes back to an incidental study finding of Professor Christoph Wanner, President of the ERA-EDTA.
Health, ...Treatment with dexpramipexole a novel drug believed to prevent dysfun... Today there are only two FDA-approved drugs used to treat ALS riluzo...Also known as Lou Gehrigs disease ALS is a progressive neurodegenera...Several investigators from Knopp which sponsored the study reported i...,Novel,ALS,drug,slows,symptom,progression,,reduces,mortality,in,phase,2,trial,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Abstract: The development of statistical approaches for the joint modelling of the temporal changes of imaging, biochemical, and clinical biomarkers is of paramount importance for improving the understanding of neurodegenerative disorders, and for providing a reference for the prediction and quantification of the pathology in unseen individuals. Nonetheless, the use of disease progression models for probabilistic predictions still requires investigation, for example for accounting for missing observations in clinical data, and for accurate uncertainty quantification. We tackle this problem by proposing a novel Gaussian process-based method for the joint modeling of imaging and clinical biomarker progressions from time series of individual observations. The model is formulated to account for individual random effects and time reparameterization, allowing non-parametric estimates of the biomarker evolution, as well as high flexibility in specifying correlation structure, and time transformation ...
the patient population who may be at high risk for disease progression. In the absence of these biologic assays, lack of disease progression is an important end point and, if quantified, may be the best indicator that TKI therapy is really impacting. ...
Biomarkers are used to detect, predict disease susceptibility and monitor disease progression for infectious diseases, cancer, metabolic diseases, central
The present invention is related generally to a method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. The present invention is also related to the diagnosis of diabetes to monitor disease progression or treatment efficacy of candidate drugs.
Understanding signs & symptoms of your condition is important. Read the common symptoms and how to monitor disease progression. See full safety & Boxed Warning.
The previously reported relationship of inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis) and ... Tsopanoglou NE, Maragoudakis ME (February 2004). "Role of thrombin in angiogenesis and tumor progression". Seminars in ... Various rare diseases involving prothrombin have been described (e.g., hypoprothrombinemia). Anti-prothrombin antibodies in ... Bernstein CN, Sargent M, Vos HL, Rosendaal FR (February 2007). "Mutations in clotting factors and inflammatory bowel disease". ...
"Aluminum involvement in the progression of Alzheimer's disease". Journal of Alzheimer's Disease. 35 (1): 7-43. doi:10.3233/JAD- ... Alzheimer disease with concomitant dementia with Lewy bodies (AD+DLB)[edit]. The degree of NFT involvement in AD is defined by ... "Journal of Alzheimer's Disease. 40 (4): 765-838. doi:10.3233/JAD-132204. PMID 24577474. S2CID 6650221.. ... 3.4 Alzheimer disease with concomitant dementia with Lewy bodies (AD+DLB). *3.5 Link to aggression and depression in people ...
... progression of the disease. Also, three classes of diabetes medications - GLP-1 agonists, DPP-4 inhibitors, and SGLT2 ... "CDC - Chronic Kidney Disease - Glossary". Retrieved 2015-07-02.. *^ Koroshi, A (2007). "Microalbuminuria, is it so important?" ... Nutrition Therapy for Chronic Kidney Disease. CRC Press. p. 198.. *^ Afkarian M, Zolnick LR, Hall YN, et al. Clinical ... "International Journal of Nephrology and Renovascular Disease. 7: 361-381. ISSN 1178-7058. PMC 4206379 . PMID 25342915. doi: ...
"Progression rate of myelopathy in X-linked adrenoleukodystrophy heterozygotes". Metabolic Brain Disease. 30 (5): 1279-84. doi: ... Puck JM, Willard HF (January 1998). "X inactivation in females with X-linked disease". The New England Journal of Medicine. 338 ... An extreme case of this was seen where monozygotic female twins had extreme variance in expression of Menkes disease (an X- ... For example, a female heterozygous for haemophilia (an X-linked disease) would have about half of her liver cells functioning ...
"A network diffusion model of disease progression in dementia". Neuron. 73 (6): 1204-15. doi:10.1016/j.neuron.2011.12.040. PMC ... Alzheimer's disease[edit]. The PCC is commonly affected by neurodegenerative disease.[15] In fact, reduced metabolism in the ... a risk factor associated with the disease).[4] It has been found that neurodegenerative diseases spread 'prion-like' through ... 1999) show that experimental damage of the rhinal cortex results in hypometabolism of the PCC.[16] In Alzheimer's disease, ...
"Progression Rate of Myelopathy in X-linked Adrenoleukodystrophy Heterozygotes". Metabolic Brain Disease Metab Brain Dis. 30 (5 ... An extreme case of this was seen where monozygotic female twins had extreme variance in expression of Menkes disease (an X- ... Puck, J; Willard, HF (1998). "X Inactivation in Females with X-Linked Disease". N. Engl. J. Med. 338 (5): 325-8. doi:10.1056/ ... For example, a female heterozygous for haemophilia (an X-linked disease) would have about half of her liver cells functioning ...
The disease is bilateral. Ocular GME is considered to be an extension of CNS disease. The blood vessels of the posterior ... It has an acute progression over a few weeks. Symptoms include incoordination, nystagmus, head tilt, seizures, and depression. ... The disease is more common in female toy dogs of young and middle age. It has a rapid onset. The lesions of GME exist mainly in ... The disease may be inherited in Pugs and Maltese and has been diagnosed in other breeds as well (Yorkies, Chihuahuas). It ...
Late in the disease's progression, hypnagogic myoclonus can occur. Tachycardia and hypertension are sometimes also present. ... The progression of SPS depends on whether it is a typical or abnormal form of the condition and the presence of comorbidities. ... As the disease progresses, patients sometimes become unable to walk or bend. Chronic pain is common and worsens over time but ... It takes an average of six years after the onset of symptoms before the disease is diagnosed. There is no evidence-based ...
... genetic and immunological basis for disease non-progression". Journal of General Virology. 92 (2): 247-268. doi:10.1099/vir. ... Genetic traits that may affect progression include: Gene mutation. A mutation in the FUT2 gene affects the progression of HIV-1 ... "HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women". AIDS. 13 (14): 1990-1991. doi: ... It is believed that the Δ32 (delta 32) variant of CCR5 impairs HIV ability to infect cells and cause disease. An understanding ...
... progression of stiffness, lordosis, and triggered spasms.[40] The name of the disease was shifted from "stiff-man syndrome" to ... Late in the disease's progression, hypnagogic myoclonus can occur.[11] Tachycardia and hypertension are sometimes also present. ... The rarity of the disease complicates efforts to establish guidelines.[30] GABAA agonists,[2] usually diazepam but sometimes ... The progression of SPS depends on whether it is a typical or abnormal form of the condition and the presence of comorbidities. ...
The disease progression of DN involves various clinical stages: hyperfiltration, microalbuminuria, macroalbuminuria, nephrotic ... Disease, Ethnicity & (2018-10-17). "Correction: Ethn Dis. 2010;20:[Suppl 1]:S1-60-S1-64". Ethnicity & Disease. 28 (4): 586. doi ... Diabetic nephropathy is one of the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) globally. ... "Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes". New England Journal of Medicine. 375 (4): 323-334. doi: ...
Parkinson's disease and Lewy body dementia[edit]. Parkinson's disease is linked with Lewy body dementia for their similar ... Insight is gradually reduced with the progression of this disorder. Sleep is disturbed and occurs for a shorter period of time ... Disorders such as Wilson's disease, various endocrine diseases, numerous metabolic disturbances, multiple sclerosis, systemic ... Parkinson's disease is usually associated with a degraded substantia nigra pars compacta, but recent evidence suggests that PD ...
The Aztecs codices give ample depictions of the disease's progression. It was known to them as the huey ahuizotl (great rash). ... Cuitlahuac contracted the disease and died after ruling for eighty days. Though the disease drastically decreased the numbers ... malnutrition or other diseases.[27] Diseases like smallpox could travel great distances and spread throughout large populations ... of its population from smallpox and other diseases.[28] The disease killed an estimated forty percent of the native population ...
"Aldosterone antagonists for preventing the progression of chronic kidney disease". Cochrane Database of Systematic Reviews. 4 ( ... Drugs and liver disease are the most common cause in adults. Other medications such as methadone, aldosterone antagonists ( ... Certain health problems in men such as liver disease, kidney failure or low testosterone can cause breast growth in men. ... In rare cases, gynecomastia has been known to occur in association with certain disease states. The pathologic causes of ...
The old classification placed too much emphasis on the age of disease onset and rate of progression, which are often difficult ... Periodontal diseases[edit]. Periodontal disease encompasses a number of diseases of the periodontal tissues that result in ... "Gum Disease: Causes, Prevention, & Treatment of Gum Disease". Colgate® Australia.. *^ a b Genco, Robert J.; Borgnakke, Wenche S ... Untreated, these diseases can lead to alveolar bone loss and tooth loss. As of 2013[update], Periodontal disease accounted for ...
Studies have also shown a progression of dysprosody over time in patients with Parkinson's disease. Abnormalities in speech ... Skodda, Sabine; Rinsche, Heiko; Schlegel, Uwe (2009). "Progression of dysprosody in Parkinson's disease over time-A ... Miller, Nick (2012). "Speech, voice and language in Parkinson's disease: Changes and interventions". Neurodegenerative Disease ... Parkinson's disease is a chronic neurodegenerative disorder that involves the loss of dopaminergic neurons in the brain. While ...
Progression[edit]. As the disease progresses one of three groups of symptoms predominate. These are: *Parkinsonism (slow, stiff ... The current terminology and diagnostic criteria for the disease were established at a 2007 conference of experts on the disease ... At some point in the progression of the disease, fluid and food modification may be suggested. Speech changes mean that ... MSA, Parkinson's disease, the Lewy body dementias, and other more rare conditions make up the synucleinopathies- ...
The authors also found that men with carotid stenosis or ischemic heart disease were at greater risk for the progression of ... atherosclerosis . Atherosclerosis can lead to coronary artery disease, carotid artery disease, peripheral artery disease, and ... "Diseases and Conditions: Varicose veins". Mayo Clinic. Retrieved December 22, 2015. "Society of Interventional Radiology- ... 2000) the authors examined the relationship between standing at work and the progression of carotid atherosclerosis in men. ...
Eddy AA, Neilson EG (November 2006). "Chronic kidney disease progression". Journal of the American Society of Nephrology. 17 ( ... Smad3 knockout mice display reduced progression of renal fibrosis, suggesting its importance in regulating the disease. ... In adult cells, TGF-β inhibits cell cycle progression, stopping cells from making the G1/S phase transition. This phenomenon is ... This loss of TGF-B inhibition results in increased amounts of active Smad2/3, which contribute to the progression of renal ...
Correlation with disease progression?". Tumori. 94 (3): 384-8. doi:10.1177/030089160809400315. hdl:2158/359919. PMID 18705407. ... The Journal of Infectious Diseases. 198 (11): 1643-50. doi:10.1086/593065. PMID 18954265. Perko R, Kang G, Sunkara A, Leung W, ... "T-gammadelta receptor restriction in peripheral lymphocytes of patients with Behçet's disease". Advances in Experimental ...
... is a chronic disease with slow progression and often subtle symptoms. It is difficult to diagnose, as many other ... Because roses can spread the disease, it is one of a few diseases referred to as rose-thorn or rose-gardeners' disease.[3] ... Sporotrichosis (also known as "rose gardener's disease"[1]) is a disease caused by the infection of the fungus Sporothrix ... Ulcerative skin disease in a cat with Sporotrichosis; a cat with this disease must be handled with caution as this form can be ...
Given the high susceptibility for disease progression of the individual with AgP, there is a higher risk of disease recurrence. ... With an increase in the age of the patient, there may be progression of the disease involving the adjacent teeth and lead to ... The difference is that individuals affected by GAP are much younger and the progression of disease appears more rapid.[30] ... If the disease is stabilised, the treatment progresses on to the maintenance stage. In the case where the disease is not ...
"A randomized trial of multivitamin supplements and HIV disease progression and mortality". N Engl J Med. 351 (1): 23-32. doi: ... a b c d e A global business built on vitamins - and the claim to kill all disease, by Sarah Bosely. Published in The Guardian ... Rath has claimed that his vitamin treatments can cure all forms of cancer, as well as most infectious diseases, including AIDS. ... cardiovascular disease, cancer, and HIV/AIDS.[7][8] These claims are not supported by any reliable medical research.[9][10] ...
Pathology - study of disease, including the causes, course, progression and resolution thereof. ... Illness (diseases and disorders)[edit]. Main articles: Lists of diseases and List of disorders ... Infectious disease - branch of medicine that deals with the diagnosis and management of infectious disease, especially for ... List of infectious diseases *List of infectious diseases causing flu-like syndrome ...
2004). "Circulating Tumor Cells, Disease Progression and Survival in Metastatic Breast Cancer". NEJM. 351 (8): 781-91. doi: ... The important aspect of the ability to prognose the future progression of the disease is elimination (at least temporarily) of ... The ability to monitor the disease progression over time could facilitate appropriate modification to a patient's therapy, ... disease progression, and treatment effectiveness.[11] CTCs thus could be considered a "liquid biopsy" which reveals metastasis ...
"Epigenomics of Alzheimer's disease progression". MIT News. Retrieved 2018-07-19. "Manolis Kellis - Cure Alzheimer's Fund". Cure ... heart disease, and cancer. To date, his lab has developed specific domain expertise in obesity, diabetes, Alzheimer's disease, ... "Kellis to lead MIT team in new phase of GTEx project to elucidate basis of disease predisposition". MIT News. Retrieved 2018-07 ... A major focus of his work is understanding the effects of genetic variations on human disease, with contributions to obesity, ...
"Epigenomics of Alzheimer's disease progression". MIT News. Retrieved 2017-03-21. Gjoneska, Elizabeta; Pfenning, Andreas R.; ... for her research on Alzheimer's disease and the role of CDK5 and chromatin remodeling in the progression of the disease. ... In more recent work, Tsai has created a lab-engineered model of the Blood-Brain Barrier to investigate how Alzheimer disease ... Tsai has elucidated the role of structural and epigenetic mechanisms in Alzheimer's disease, showing in two 2015 studies that ...
... structural and functional progression monitoring; non-evasive imaging of diseases such as glaucoma; brain and eye physiology; ... 62/65,304, Methods and systems for patient specific identification and assessment of ocular disease risk factors He developed ... "African and European Descent, Ocular Blood Flow and Glaucoma Progression". Cite journal requires ,journal= (help) Guidoboni, ... "Methods And Systems For Patient Specific Identification And Assessmentof Ocular Disease Risk Factors And Treatment Efficacy ...
... disease molecular signatures); and disease evolution and progression. Investigators can analyze genome, methylome, epigenome, ... Each patient has a unique disease process ("the unique disease principle"), considering the uniqueness of the exposome and its ... It is defined as "epidemiology of molecular pathology and heterogeneity of disease". Pathology and epidemiology share the same ... Rescigno T, Micolucci L, Tecce MF, Capasso A (2017). "Bioactive Nutrients and Nutrigenomics in Age-Related Diseases". Molecules ...
Coronary artery disease (CAD)- Coronary artery disease is a general term for any reduction in coronary circulation. One such ... Progression to eclampsia involves seizures. Currently, the only definitive treatment is delivery of the fetus. Hemorrhagic ... Diseases of blood vessels - diseases of the blood vessels can be multidisciplinary in nature. For example, medical treatment of ... Carotid artery - Diseases of the carotid arteries: Carotid artery stenosis / carotid artery disease - Narrowing of the carotid ...
The progression of hair loss is unpredictable. In some cases, progression is slow and there is always sufficient hair remaining ... Surgical treatment for cosmetic benefit is an option in some cases after the disease has been inactive for one to two or more ... It is important to continue to watch for symptoms and signs of active disease during and after treatment to ensure that the ... Photographs of the scalp may be useful in monitoring the course of the disease and response to treatment. The cause of the ...
... should receive an inhibitor of the renin-angiotensin system to reduce the risks of progression to end-stage renal disease, ... Diseases of the endocrine system (ICD-10 Chapter IV: Endocrine, nutritional and metabolic diseases - Endocrine diseases, E00- ... Diabetes was one of the first diseases described.[21] The importance of insulin in the disease was determined in the 1920s.[22] ... two to four times the risk of cardiovascular disease, including ischemic heart disease and stroke; a 20-fold increase in lower ...
... but it can extend the length of a person's life for several years by slowing the progression of the disease. The type that is ... Impairs endothelial function in healthy HIV-negative men and may accelerate atherosclerotic disease.[10] ... It significantly increased life expectancies and decreased noticeable symptoms from infectious diseases that were the result of ...
"Intercessory Prayer and Cardiovascular Disease Progression in a Coronary Care Unit Population: A Randomized Controlled Trial". ... while imbalance results in disease. Such disease-inducing imbalances can be adjusted and balanced using traditional herbs, ... A belief that a substance that causes the symptoms of a disease in healthy people cures similar symptoms in sick people.[n 8] ... Treatments for severe diseases such as cancer and HIV infection have well-known, significant side-effects. Even low-risk ...
However, decreases in this adhesion ability of the cell has been linked to metastasis and tumor progression. In normal cells, α ... MacDonald BT, Tamai K, He X (July 2009). "Wnt/β-catenin signaling: components, mechanisms, and diseases". Dev. Cell. 17 (1): 9- ... may help prevent clinical recurrence of the disease after surgery, but much more work is needed before an adequate treatment ... "The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway". ...
One of the major complications of this treatment is progression of Nelson's syndrome which is caused by enhance level of tumor ... The disease is often diagnosed 3-6 years after the onset of illness.[19] Several studies have shown that Cushing's disease is ... Cases of Cushing's disease are rare, and little epidemiological data is available on the disease. An 18-year study conducted on ... Cushing disease, tertiary or secondary hypercortisolism, tertiary or secondary hypercorticism, Itsenko-Cushing disease[1][2]. ...
SP concentrations cannot yet be used to diagnose disease clinically or gauge disease severity. It is not yet known whether ... Muñoz M, Coveñas R (Oct 2013). "Involvement of substance P and the NK-1 receptor in cancer progression". Peptides. 48: 1-9. doi ... Microbial Toxins and Diarrhoeal Disease. Ciba Found. Symp. 112. pp. 139-54. doi:10.1002/9780470720936.ch8. PMID 2861068.. ... Quantification in diseaseEdit. Elevation of serum, plasma, or tissue SP and/or its receptor (NK1R) has been associated with ...
"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and ... Graft-versus-host disease[edit]. Main article: Graft-versus-host disease. Graft-versus-host disease (GVHD) is an inflammatory ... Veno-occlusive disease[edit]. Severe liver injury can result from hepatic veno-occlusive disease (VOD). Elevated levels of ... Major complications are veno-occlusive disease, mucositis, infections (sepsis), graft-versus-host disease and the development ...
Pathology as a science is the study of disease-the causes, course, progression and resolution thereof. ... listen)) is the science and practice of the diagnosis, treatment, and prevention of disease.[4][5] The word "medicine" is ... Preventive medicine is the branch of medicine concerned with preventing disease. *Community health or public health is an ... Pathology as a medical specialty is the branch of medicine that deals with the study of diseases and the morphologic, ...
Interstitial lung disease. Mechanism of action[edit]. Like lapatinib and neratinib, afatinib is a protein kinase inhibitor that ... "Afatinib (BIBW 2992*) Triples Progression Free Survival in Phase III Study in Lung Cancer Patients". BusinessWire. 11 October ... Fall 2010 interim results suggested the drug extended progression-free survival threefold compared to placebo, but did not ...
... effective at reducing the symptoms of Alzheimer's and it was hoped that they could also slow the progression of the disease, ... One data set went to the FDA's Division of Neurology Drug Products for the treatment of Alzheimer's disease, while the other ... 2006 by the Neurology Division a dose was permitted for continuing a study in patients with Alzheimer's disease, but that dose ... and continue its study of CX717 in its Alzheimer's disease PET scan study. Cortex believes that the IND application previously ...
Symptoms of disease are more severe in males, who are generally diagnosed in early childhood. Children afflicted by CLS display ... The progression of reduced cardiac functioning over time may necessitate surgical procedures to counteract mitral valve ... The prevalence of CLS is uncertain due to the rarity of the disease, but CLS is estimated to affect between 1 in 50,000 and 1 ... In 20-30% of cases, however, there is a family history of disease. In these cases, the disorder is typically inherited from the ...
Richard A. Helms; David J. Quan (2006). Textbook of Therapeutics: Drug and Disease Management. Lippincott Williams & Wilkins. ... Androgens like testosterone and particularly DHT are importantly involved in the development and progression of prostate cancer ... Giuseppe Buonocore; Rodolfo Bracci; Michael Weindling (28 January 2012). Neonatology: A Practical Approach to Neonatal Diseases ... W. Futterweit (6 December 2012). Polycystic Ovarian Disease. Springer Science & Business Media. pp. 282-. ISBN 978-1-4613-8289- ...
Altering the progression of left sided heart disease". Progress in Pediatric Cardiology. 22: 71-78. doi:10.1016/j.ppedcard. ...
Parkinson's Disease and Alzheimer's Disease.[3] There is also an interest in the military potential of biological neurotoxins ... in paralytic shellfish poisoning produces a flaccid paralysis that leaves its victim calm and conscious through the progression ... "Neurobiology of Disease. 25 (2): 360-366. doi:10.1016/j.nbd.2006.10.002. PMC 3959771. PMID 17098435.. ... Byth S (July 1980). "Palm Island mystery disease". The Medical Journal of Australia. 2 (1): 40, 42. PMID 7432268.. ...
85% of MGN cases are classified as primary membranous glomerulonephritis-that is to say, the cause of the disease is idiopathic ... Corticosteroids: They have been tried with mixed results, with one study showing prevention of progression to kidney failure ... A large part of this difficulty is due to a lack of ability to predict which people will progress to end-stage kidney disease, ... Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly people between ages of 30 ...
Proceeds from its release went to the Gunnar Nilsson cancer charity, set up after the Swedish driver's death from the disease ... Harrison wrote the chord progression of "Don't Bother Me" almost exclusively in the Dorian mode, demonstrating an interest in ...
... having small numbers of large HDL particles is independently associated with atheromatous disease progression within the ... This disease process leads to myocardial infarction (heart attack), stroke and peripheral vascular disease. Since higher blood ... liver diseases, and mental diseases. This result indicates that the low cholesterol effect occurs even among younger ... which is the principal cause of coronary heart disease and other forms of cardiovascular disease. In contrast, HDL particles ( ...
Baird, Amee; Samson, Séverine (2009). "Memory for Music in Alzheimer's Disease: Unforgettable?". Neuropsychology Review. 19 (1 ... common chord progressions, scale patterns, etc.) and individual expectations of how the melody should proceed. The auditory ... Samson and Baird (2009) found that the ability of musicians with Alzheimer's Disease to play an instrument (implicit procedural ... rhythmic auditory stimuli have been shown to improve walking ability in Parkinson's disease and stroke patients.[38][39] ...
Progress in Cardiovascular Diseases. 52 (6): 467-484. doi:10.1016/j.pcad.2010.02.003. PMID 20417340.. ... High central venous pressure may also occur late in the condition's progression.[16] ...
A compound heterozygous mutation of the HADHB gene can causes axonal Charcot-Marie-tooth disease, which is a neurological ... "Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression". PLoS ONE. 5 (9): e12862. doi:10.1371/ ... "A compound heterozygous mutation in HADHB gene causes an axonal Charcot-Marie-tooth disease". BMC Medical Genetics. 14: 125. ...
... progression of FAP over a 36-month period and importantly reversed the weight loss and muscle wasting associated with disease ... or Corino de Andrade's disease,[1] is an autosomal dominant[2] neurodegenerative disease. It is a form of amyloidosis, and was ... progression. Epidemiology[edit]. This disease is endemic in Portuguese locations Póvoa de Varzim and Vila do Conde (Caxinas), ... "Rare-Disease Treatment From Alnylam to Cost $450,000 a Year". Retrieved 11 August 2018.. ...
Whether they affect the progression of the disease is unknown.[2] When used in combination with a LABA, they may decrease ... Chronic obstructive pulmonary disease. Other names. Chronic obstructive lung disease (COLD), chronic obstructive airway disease ... Most cases of COPD are a mixture of both diseases.. *^ "Chronic obstructive pulmonary disease (COPD)". WHO. Retrieved 5 June ... Wikimedia Commons has media related to Chronic obstructive pulmonary disease.. *Chronic obstructive pulmonary disease at Curlie ...
2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. p. 269. ISBN 0-7216-2921-0.. ... Progression to toxemia and shock is often very rapid. It can easily be noticed by the large, blackened sores that form, as well ... Pailler JL, Labeeu F (1986). "[Gas gangrene: a military disease?]". Acta Chir. Belg. (in French). 86 (2): 63-71. PMID 3716723. ...
Not all people with Hunter syndrome are affected by the disease in the same way, and the rate of symptom progression varies ... Hunter syndrome is one of several related lysosomal storage diseases called the MPS diseases. In Hunter syndrome, GAGs build up ... the effects of even mild disease are quite serious. Between the two main forms of disease, and even within them, two of the ... In Gangtok, the 8-year-old son of the editor of 'Voice of Sikkim' also suffers from the disease. A study in the United Kingdom ...
This has implications for the treatment of various autoimmune diseases (e.g. multiple sclerosis, type-1 diabetes, and ... The covalent linkage impedes replication fork progression. Thus unlinking the ICL is required before replication can resume. ... for the suppression of effector memory T cells in autoimmune diseases". Molecular Pharmacology. 68 (5): 1254-1270. doi:10.1124/ ...
... reduces progression to end-stage kidney disease at three months.[9]. Oral and intravenous cyclophosphamide are both effective ... Limited diseaseEdit. In generalised non-organ-threatening disease, remission can be achieved with a combination of methotrexate ... An early name for the disease was pathergic granulomatosis.[28] The disease is still sometimes confused with lethal midline ... GPA treatment depends on the severity of the disease.[8] Severe disease is typically treated with a combination of ...
... a biomarker indicates a change in expression or state of a protein that correlates with the risk or progression of a disease, ... is a DNA sequence that causes disease or is associated with susceptibility to disease. They can be used to create genetic maps ... It can also be a substance whose detection indicates a particular disease state, for example, the presence of an antibody may ... or with the susceptibility of the disease to a given treatment. One example of a commonly used biomarker in medicine is ...
Immune-mediated eye disease can cause ulcers at the border of the cornea and sclera. These include Rheumatoid arthritis, ... The typical feature of fungal keratitis is slow onset and gradual progression, where signs are much more than the symptoms. ... Corneal ulcers are a common human eye disease. They are caused by trauma, particularly with vegetable matter, as well as ...
... pathways through which factors act to enhance vascular disease regression and prevent disease development/progression. In 1946 ... in heart diseases). She further determined how these cells could be maintained in the 'non-disease' phenotype. This knowledge ... This process is undergoing pre-clinical trials in humans and may be used to treat patients suffering coronary heart disease, ... This 'Grow Your Own Arteries' technique is helping patients survive coronary heart disease, renal failure and other life- ...
A novel machine-learning tool that uses genetic data from patient blood samples can strongly predict the progression and ... severity of neurodegenerative diseases such as Alzheimers and Huntingtons. ... Cite this: AI Blood Test Predicts Neurodegenerative Disease Progression, Severity - Medscape - Feb 07, 2020. ... Going forward, he and his colleagues plan to test their predictive model in such diseases as Parkinsons disease and ...
Learn more about its progression and the outlook for people with this condition here. ... Alzheimers disease is a type of dementia that affects many people as they get older. ... Disease-modifying therapies may be most effective in the early stages of Alzheimers, and they could slow disease progression. ... Factors that can affect disease progression include:. Age: People with symptoms of Alzheimers that develop before the age of ...
encoded search term (What is the disease progression of dengue?) and What is the disease progression of dengue? What to Read ... What is the disease progression of dengue?. Updated: May 03, 2019 * Author: Darvin Scott Smith, MD, MSc, DTM&H; Chief Editor: ... The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap ... Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for ...
Psoriasis is a chronic inflammatory disease that affects about 6.7 million adults in the United States, according to recent ... A new study suggests that adhering to a Mediterranean diet may relieve the severity of psoriasis and slow its progression. ... "T]his finding supports the hypothesis that the Mediterranean diet may slow the progression of psoriasis. If these findings are ... has shown that pro-inflammatory compounds including saturated fats can worsen conditions such as inflammatory bowel disease and ...
Volume progression in polycystic kidney disease.. Brosnahan GM.. Comment on. *Volume progression in polycystic kidney disease. ...
Metabolome in progression to Alzheimers disease.. Orešič M1, Hyötyläinen T, Herukka SK, Sysi-Aho M, Mattila I, Seppänan-Laakso ... We sought to determine the serum metabolomic profiles associated with progression to and diagnosis of AD in a prospective study ... A molecular signature comprising three metabolites was identified, which was predictive of progression to AD in the follow-up. ... Mild cognitive impairment (MCI) is considered as a transition phase between normal aging and Alzheimers disease (AD). MCI ...
... signaling axis is needed for periodontal disease progression: an orally administered p38α inhibitor reduced the progression of ... MAPK Usage in Periodontal Disease Progression. Qiyan Li,1 Michael S. Valerio,2 and Keith L. Kirkwood2 ... MAPK phosphatase-1 (MKP-1), a negative regulator of MAPK activation, was also critical for periodontal disease progression. In ... these studies highlight the importance of p38 MAPK signaling in immune cytokine production and periodontal disease progression. ...
... predicted future loss of brain tissue in people with Alzheimers disease. ... Studies estimate that more than 5 million people in the U.S. are living with Alzheimers disease. That number is expected to ... The participants in the study were relatively young for people with Alzheimers disease: 63% were under the age of 65 when they ... More work is needed to understand other factors that can help predict loss of brain tissue in Alzheimers disease. ...
Brain activity in patients with Parkinsons disease and 2 Parkinsons-like disorders showed unique patterns of activity over ... Parkinsons Disease Information Page. References: Functional MRI of disease progression in Parkinson disease and atypical ... Tracking parkinsonian disease progression. At a Glance. *Researchers measured brain activity in patients with Parkinsons ... "This study is an example of how brain imaging biomarkers can be used to monitor the progression of Parkinsons disease and ...
Progression of non-squamous non-small cell lung cancer slowed by almost half when pemetrexed (Alimta) and erlotinib (Tarceva) ... The progression hazard ratio was 0.57 for the comparison with erlotinib alone (P=0.002) and 0.58 for the comparison with ... Progression of non-small cell lung cancer slowed by almost half when pemetrexed (Alimta) and erlotinib (Tarceva) were used in ... VIENNA -- Progression of non-squamous non-small cell lung cancer (NSCLC) among never- and former light-smoker patients slowed ...
Findings from a recent study could pave the way for a new treatment target for Huntingtons disease that utilizes ... but not late-disease stages and that targeting these complexes could potentially slow the progression of early-stage diseases ... Antihistamines could slow progression of Huntingtons disease. Researchers say the drug could help ease patients symptoms in ... "The imbalance of dopamine signalling in disease progression represents a potential point of no return for Huntingtons ...
Parts 1 through 3 describe different disease outcomes that occur in coast live oak, Quercus agrifolia. Part 4 describes disease ... Sudden oak death is a lethal disease that affects several species of oaks and tanoak. ...
Kidney disease may progress faster for diabetics who have kidney disease and also suffer from sleep apnea, according to a new ... home/sleep center/ sleep a-z list/ sleep apnea linked to kidney disease progression article ... 14, 2014 (HealthDay News) -- Kidney disease may progress faster for diabetics who have kidney disease and also suffer from ... Disease & Conditions Conditions A-Z Procedures A-Z Allergies Alzheimers Arthritis Asthma Blood Pressure Cancer Cholesterol ...
Alkali therapy, whether pharmacologically or through dietary intervention, appears to slow CKD progression, but an ... of work in animals and human beings supports the hypothesis that metabolic acidosis has a deleterious effect on the progression ... Acid Base Balance and Progression of Kidney Disease Semin Nephrol. 2019 Jul;39(4):406-417. doi: 10.1016/j.semnephrol.2019.04. ... and human beings supports the hypothesis that metabolic acidosis has a deleterious effect on the progression of kidney disease ...
Researchers stop Parkinsons disease progression in mice by blocking astrocyte conversion. Credit: iStock ... Researchers say they have developed an experimental drug that slows the progression of Parkinsons disease itself ... that slows the progression of Parkinsons disease itself - as well as its symptoms - in mice. In experiments performed with ... it could be one of the first treatments to directly target the progression of Parkinsons disease, not just the muscle rigidity ...
... typical acute retroviral syndrome disease progression, with a wealth of fact sheets, expert advice, community perspective, the ... thrush= disease progression?. Hello Dr. Feinberg,Ive been trying to get answer to this for months, but no luck. A bit ... Acute HIV infection or Disease progression?. Dr. Holodniy,My last negative HIV test was May of 1999. In November and December I ... The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is ...
Using the IoT and machine learning to track the progression of lung disease in new project with IBM Research and a Swiss start- ... Using IoT and machine learning to track the progression of lung disease IBM scientists Thomas Brunschwiler and Rahel Straessle ... In the future, the algorithms derived from these patterns could be useful to identify the status and progression of the disease ... Chronic obstructive pulmonary disease, a.k.a. COPD, is a progressive lung disease which causes breathlessness and is often ...
Progression Markers Initiative provides a unique opportunity to gain insights into the progression of Parkinsons disease. By ... Impact on Diagnosis/Treatment of Parkinsons Disease:Understanding how the disease progresses in different patient cohorts may ... We will create a robust assessment score after tuning the models for the specific disease findings. With feedback from subject ... Using these tools in other disease states, we have successfully identified this type of detail. Study Design:Initially, data ...
About Huntingtons disease. Huntingtons disease is a fatal genetic neurological disease. It usually develops in adulthood and ... The first blood test that can predict the onset and progression of Huntingtons disease has been identified by a UCL-led study ... Blood test can predict onset and track progression of Huntingtons disease. 8 June 2017 ... which has been linked to other neurodegenerative diseases but hasnt been studied in the blood of Huntingtons disease (HD) ...
Finasteride Reduces Symptoms And Disease Progression Associated With Enlarged Prostates. by Sam Savage ... and reduces disease progression. This conclusion comes from combining the findings of 23 randomized clinical trials that ... Drugs like finasteride are frequently prescribed to improve LUTS and reduce long-term symptom progression, including the risk ...
... Protective effects of azithromycin treatment in ... "Previous studies have suggested that COPD may be a disease of accelerated aging for a variety of reasons including its close ... It is known that short telomeres are associated with common comorbidities of COPD, such as cardiovascular disease and cancer, ... Its mission is to champion the prevention, diagnosis and treatment of chest diseases through education, communication and ...
Researchers may be one step closer to slowing the onset and progression of Alzheimers disease. An animal study supported by ... and common diseases to help prevent disease and improve human health. ... The vision of the NIEHS is to use environmental health sciences to understand human disease and improve human health. Use the ... One of the challenges confronting the diagnosis and treatment of Alzheimers is being able to clearly diagnose the disease ...
The primary study outcome will be progression of periodontal disease as determined by CAL. Initial disease progression at a ... Biomarkers of Periodontal Disease Progression. The safety and scientific validity of this study is the responsibility of the ... Subsequent disease progression will be similarly defined except that the loss in CAL will be compared with the last visit at ... Biomarkers of Periodontal Disease Progression Brief Summary The primary purpose of the study will be to look for biological ...
Researchers say vitamin E might slow the progression of mild-to-moderate Alzheimers disease - the first time any treatment has ... Researchers say vitamin E might slow the progression of mild-to-moderate Alzheimers disease - the first time any treatment has ... Antioxidants help protect cells from damage that can contribute to other diseases, says the federal Office on Dietary ... "The best we can do at this point is slow down the rate of progression." ...
Diabetic drug could slow the progression of Parkinsons disease *A hallmark of Parkinsons disease is the degeneration of a ... A hallmark of Parkinsons disease is the degeneration of a group of dopaminergic neurons in the brain, which play key roles in ... "It is possible that existing drugs could be repurposed for treating different diseases. It is known that patients treated for ... with the number of these Lewy bodies present correlating with the severity of the disease. Early stages in the aggregation of ...
Population geneticist Stephen OBrien of the National Cancer Institute and a large group of collaborators have amassed strong confirmatory evidence that people who have two mutant copies of the gene for a chemokine receptor known as CCR5 (also known as CKR5) are highly resistant to HIV infection. The findings, published on page1856 , also indicate that people who do get infected with HIV, but have one mutant copy of the CCR5 gene, progress to AIDS more slowly than do people without the mutation.. ...
There is widespread agreement that LVH is an important intermediate phenotype in the progression of hypertensive heart disease1 ... The classic paradigm of the progression of hypertensive heart disease is that hypertension does not lead to dilated cardiac ... Challenges to the Classic Paradigm of the Progression of Hypertensive Heart Disease ... 1 The purpose of this review is to focus on the key steps in the progression of hypertensive heart disease (Figure 1), ...
Stage 2 the disease has come outside the pleura and invaded into the fatty tissue of lung or the diaphragm. Stage 3 is where ... The TNM system measures cancer progression based on three key factors:. *Size of the main tumor (T): How far the cancer has ... The disease may, instead, be described as localized, regional, or distant using the SEER staging system. Doctors may also ... Numbers and/or letters after the T, N, and M detail the progression of these three factors. For example, T1 describes a tumor ...
... personalized treatments are developed to slow disease progression, there is a vital need for imaging methods that can detect ... As new, personalized treatments are developed to slow disease progression, there is a vital need for imaging methods that can ... Here are some of the ways we are making disease progression (or regression) easier for radiologists to monitor. ... application provides features and tools to decrease the time required to implement RECIST into disease progression tracking, as ...
  • Feasibility of predicting Alzheimer's disease (AD), based on concentrations of three metabolites (2,4-dihydroxybutanoic acid, unidentified carboxylic acid, phosphatidylcholine (PC (16:0/16:0)) in subjects at baseline, who were diagnosed with mild cognitive impairment (MCI). (
  • Alzheimer's disease (AD) is a chronic neurodegenerative disease, and its long-term progression prediction is definitely important. (
  • People with type 2 diabetes are also at greater risk for chronic kidney disease (CKD), according to background information from the study. (
  • Chronic obstructive pulmonary disease, a.k.a. (
  • As most chronic diseases progress outside the hospital we need a secure way to monitor patients when they are discharged," said Dr. Ulrich Muehlner, CEO, (
  • 850 million people worldwide are affected by chronic kidney disease (CKD) - a worrying figure, and one that continues to rise. (
  • We wanted to find a therapy to improve cardiovascular outcomes in individuals with type 2 diabetes and found a long-awaited treatment to slow progression of chronic kidney disease, even in those who do not suffer from type 2 diabetes. (
  • According to the Canadian Medical Association Journal , up to five per cent of people with chronic obstructive pulmonary disease (COPD) are thought to have alpha-1 antitrypsin deficiency, yet only four to five per cent of those with a deficiency have been identified. (
  • Be aware that this study suggests that ACE inhibitor therapy on top of standard antihypertensive treatment can significantly slow progression of chronic renal insufficiency even when advanced. (
  • GUANZHOU, China, Jan. 11 - Aggressive treatment with ACE inhibitors may slow the progression of chronic renal insufficiency in patients without diabetes, researchers here reported. (
  • Nonetheless," they added, "blood pressure, renal function, and serum potassium levels should be monitored regularly in patients with advanced chronic kidney disease, especially during the first two months of ACE-inhibitor therapy and as renal function changes. (
  • Fifteen years ago, Fine et al 1 first presented the chronic hypoxia hypothesis about the progression of chronic kidney disease. (
  • Subsequent refinement of this hypothesis has led to the proposition that multiple forms of chronic kidney disease are, at least partly, driven by a vicious cycle of hypoxia, renal inflammation, and fibrosis, which inexorably leads to failure of glomerular filtration (Figure). (
  • However, it must also be said that much of the evidence to support these statements comes from in vitro studies, often using cultured cells, rather than from in vivo studies using experimental models of chronic kidney disease. (
  • Thus, we still have some way to go to understand the molecular mechanisms linking hypoxia and the progression of chronic kidney disease. (
  • 10 Department of Chronic Disease Prevention, The National Institute for Health and Welfare, Helsinki, Finland. (
  • Here we evaluated the performance of a large set of serum biomarkers for the prediction of rapid progression of chronic kidney disease (CKD) in patients with type 2 diabetes. (
  • Pharmaceuticals have made a significant contribution to the treatment of lifestyle-related diseases and other chronic diseases such as diabetes and cardiovascular diseases. (
  • With Sphere "Chronic Disease Progression Prevention," we aim to prevent the onset and severity of chronic diseases such as lifestyle-related diseases by providing solutions for disease management and prevention of severity based on scientific evidence. (
  • These methods provide both a powerful set of tools and a rich conceptual framework for thinking about disease progression and related problems, and they could find application in the study of a wide range of chronic diseases. (
  • If acute hepatitis C infection (HCV) becomes a chronic infection it can eventually progress to a more serious disease. (
  • The AI-powered system is also touted for detecting tuberculosis, chronic obstructive pulmonary disease, lung malignancies and medical emergencies including lung collapses and cardiac disorders. (
  • Although it was once believed that most chronic kidney disease inevitably progressed to end stage renal disease, we now know that it is possible to slow or even halt the progression of kidney disease. (
  • Dual energy x ray absorptiometry (DEXA) is an established method to measure thigh muscle mass in chronic obstructive pulmonary disease (COPD). (
  • Through counteracting chronic inflammation, the progression of the disease could be prevented. (
  • By signaling through the UPR, you end up with this chronic state of inflammation that is detrimental, which contributes to the progression of the disease. (
  • Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries and is associated with aging and features of metabolic syndrome. (
  • From 2000 to 2015, death rates for chronic liver disease and cirrhosis in the United States increased 31%, according to the CDC. (
  • Chronic liver disease and cirrhosis can contribute to the development of liver cancer, which affects approximately 33,000 individuals in the United States each year. (
  • Multiple sclerosis (MS) is a chronic, progressive disease of the central nervous system with high costs in terms of disability adjusted life years, medical costs and wider economic costs to society. (
  • The present invention provides a sensor or a system comprising gold nanoparticles coated with specific organic coatings for diagnosing, staging or monitoring chronic kidney disease. (
  • Limited-protein diet: a means of delaying the progression of chronic renal disease? (
  • Chronic kidney disease (CKD) affects about 750 million people each year, with global deaths predicted to rise from 1.2 million in 2016 to 3.1 million in 2040. (
  • Researchers find that a certain gene mutation might predict Alzheimer's progression. (
  • Researchers from University of Wisconsin School of Medicine in Madison recently set out to investigate whether they could identify an early marker for Alzheimer's disease. (
  • Researchers are studying this preclinical stage to work out which factors can predict the risk of progression from normal cognition to stage 2 of Alzheimer's disease. (
  • In order to better understand whether tau tangles and amyloid plaques may predict the development of Alzheimer's, researchers need to be able to track tau and amyloid in the brain as disease develops. (
  • Researchers measured brain activity in patients with Parkinson's disease and 2 Parkinson's-like disorders over a year. (
  • however, the researchers observed that as the disease progressed, which was typically around the six- to eight-month mark, they were no longer working cohesively. (
  • The researchers, led by Dr. Roberto Pisoni of the Medical University of South Carolina, investigated whether sleep apnea was linked to diabetes and the development of kidney disease. (
  • Researchers stop Parkinson's disease progression in mice by blocking astrocyte conversion. (
  • Johns Hopkins researchers say they have developed an experimental drug, similar to compounds used to treat diabetes, that slows the progression of Parkinson's disease itself - as well as its symptoms - in mice. (
  • Similar but untreated mice injected with alpha-synuclein showed pronounced motor impairment over the course of six months in behavioral tests such as the pole test, which allows researchers to measure motor impairment such as that caused by Parkinson's disease. (
  • The researchers say that predicting progression in mutation carriers who do not yet show symptoms has been particularly challenging. (
  • In a new study published in the journal CHEST ® researchers report that measuring blood telomeres, a marker of aging of cells, can be used to predict future risk of the disease worsening or death. (
  • Researchers say vitamin E might slow the progression of mild-to-moderate Alzheimer's disease - the first time any treatment has been shown to alter the course of dementia at that stage. (
  • But Dr. Hebert was cautious in his interpretation of the Hou data, noting that the Chinese researchers used an ACE inhibitor dose that was half the maximal recommended dose for patients with kidney disease, which is significantly higher than the 15 to 25% of maximal dose reported by other researchers. (
  • In a study published by the Journal of the American Medical Association, researchers report that vitamin E might slow the progression of mild to moderate Alzheimer s disease. (
  • The researchers conducted blood tests, took xrays, and looked at the clinical symptoms to find markers that might show the odds for disease progression. (
  • Researchers have long understood the function of the protein, Caveolin-1 (Cav-1), in prostate cancer, including its role in treatment resistance and disease aggressiveness. (
  • Researchers from Yale University School of Medicine have discovered that defects in the transport of lysosomes within neurons promote the buildup of protein aggregates in the brains of mice with Alzheimer's disease. (
  • The researchers found that neurons lacking a protein called JIP3 failed to transport lysosomes from axons to the cell body, leading to the accumulation of lysosomes in axonal swellings similar to those seen in Alzheimer's disease patients. (
  • The researchers then removed one copy of the gene encoding JIP3--halving the amount of JIP3 protein--from mice that were already prone to developing Alzheimer's disease. (
  • Researchers at the Stanford University School of Medicine and six other institutions have designed a new diagnostic tool for a rare and deadly autoimmune disease that affects the skin and internal organs. (
  • By measuring the activity of genes in tiny skin samples, the researchers were able to predict disease progression in patients as much as a year earlier than clinicians who used standard methods for evaluating patients. (
  • A protein essential for building memories that appears to predict the progression of memory loss and brain atrophy in Alzheimer's patients has been identified by Iowa State University researchers. (
  • ISU researchers also focused their attention on the medial temporal lobe, an area of the brain that shows the first signs of memory loss or cognitive decline in Alzheimer's disease. (
  • Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, for nearly two years in one type of mouse model used to study the disease - allowing the mice to approach their normal lifespan. (
  • Using the new treatment, researchers were able to stop the progression of ALS in one type of transgenic mouse model, which ordinarily would die within two weeks without treatment. (
  • These new levels are called the "set point," and they are relevant to researchers because studies have found that they can influence how quickly or slowly a person's HIV disease will progress. (
  • Researchers looked back at the scores of those prescribed MAO-B inhibitors and found that those who took them longer had slower progression of Parkinson's (i.e., less decline on the rating scales). (
  • In order to analyze stress response network wiring, the researchers specifically studied the disease atherosclerosis, which is characterized by fat deposition in the shape of a plaque in the arteries causing an inflammatory response. (
  • Researchers have been busy conducting trials for the new drug Solanezumab, which they believe could stop the degenerative disease from progressing if patients are treated at an early stage of diagnosis. (
  • The researchers analysed medical records of patients attending their memory clinic for the first time between 1997 and 2003 inclusively who had a final diagnosis of Alzhiemer's, Alzhiemer's with cerebro-vascular disease, or vascular dementia. (
  • For this retrospective multicenter study-known as the Natural History of the Progression of Atrophy Second-ary to Stargardt Disease (ProgStar) Study-the researchers assessed 217 patients (390 eyes). (
  • Mount Sinai School of Medicine researchers have succeeded in developing a biosynthetic polyphenol that improves cognitive function in mice with Alzheimer's disease (AD). (
  • Researchers at the Feinstein Institute used PET scanning to map changes in brain metabolism in 12 people with the Huntington's disease gene who had not developed clinical signs of the illness. (
  • Researchers at the University of Texas at San Antonio have embarked on an ambitious project that combines behavioral data with cellular testing, work they hope will shed light on the development of diseases such as dementia and Alzheimer's. (
  • Researchers sought to identify the broader health, societal and economic impacts of disease progression in multiple sclerosis (MS). They found that MS is associated with high economic costs to society that go beyond costs to the healthcare system, but uncovered limited evidence on the impact of disease progression on patients, carers, and society as a whole. (
  • In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans. (
  • Researchers analyzed the effects of the treatment strategies on blood vessels in the eye by identifying diabetic retinopathy progression over four years. (
  • Researchers investigated whether long-term micronutrient supplementation is effective and safe in delaying disease progression when implemented early in adults infected with HIV subtype C who are antiretroviral therapy (ART) naive. (
  • Researchers from Japan have found a promising flavonoid in citrus fruit that could help prevent the progression of kidney disease. (
  • The researchers evaluated possible treatment options of kidney disease in the form of functional foods. (
  • Researchers from Boston wanted to see if a type of medicine called angiotensin receptor blockers , used to treat high blood pressure and heart failure, could affect the risk or progression of Alzheimer's disease. (
  • Willette and Swanson used data from the Alzheimer's Disease Neuroimaging Initiative to assess which aspects of the immune system were most relevant to tracking Alzheimer's disease progression. (
  • Alzheimer's disease is the most common form of dementia in older adults. (
  • Alzheimer's disease is a kind of dementia that gets worse over time. (
  • Dawson explains that if planned clinical trials for the drug, named NLY01, are successful in humans, it could be one of the first treatments to directly target the progression of Parkinson's disease, not just the muscle rigidity, spasmodic movements, fatigue, dizziness, dementia and other symptoms of the disorder. (
  • Previous studies have suggested that COPD may be a disease of accelerated aging for a variety of reasons including its close relation to senescence-related disorders, such as osteoporosis and dementia, and its exponential increase in prevalence beyond 50 years of age. (
  • Approximately 25% of cases had an early malignant, dementia-dominant syndrome and severe neocortical disease consistent with dementia with Lewy bodies. (
  • Beyer MK, Larsen JP, Aarsland D (2007) Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. (
  • Galvin JE, Pollack J, Morris JC (2006) Clinical phenotype of Parkinson disease dementia. (
  • This page outlines the characteristics of the early, middle and late stages of Alzheimer's disease and briefly looks at how other forms of dementia progress. (
  • The most common types of dementia - Alzheimer's disease, vascular dementia, dementia with Lewy bodies and frontotemporal dementia - are all progressive. (
  • Some of these scales were developed specifically for Alzheimer's disease and work better for that than for other types of dementia. (
  • While it can be helpful for planning ahead to have some awareness of the likely progression of a person's dementia, it is important to realise that everyone's experience will be different. (
  • There is good evidence that, by the time most people develop any symptoms of dementia , the underlying disease has been causing damage to their brain for years. (
  • It is likely that any medication designed to slow down or prevent the diseases that cause dementia would work in this early phase, before the disease is fully established. (
  • There is no cure for Alzheimer's disease or any other type of dementia. (
  • While there was no difference in motor outcomes, we observed that the risk for dementia was greater in men than in women with Parkinson's disease. (
  • Both falls and dementia are dreaded late complications of Parkinson's disease because they are resistant to medical or surgical treatments and because they carry an increased risk for nursing home placement and even death. (
  • Predicting falls and dementia as late complications of Parkinson's disease is a research priority of the Department of Neurology at NorthShore and a current focus of my research. (
  • In the UK there are 850,000 people currently suffering from dementia, and the disease is thought to kill at least 60,000 people every year. (
  • WASHINGTON, June 10, 2007 /PRNewswire-USNewswire/ -- A new study suggests that treating risk factors for heart disease and stroke, such as high blood pressure and diabetes, may slow the progression of Alzheimer's disease, according to research reported today at the 2nd Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. (
  • Most of the social and financial burden caused by Alzheimer's and dementia is generated by the later, more severe stages of the disease," Deschaintre said. (
  • By slowing dementia progression, vascular risk factors treatment may delay the severe stages and have a significant impact on reducing the burden of dementia. (
  • However, in Alzheimer's disease, frontotemporal dementia (FTD), and other "tauopathies" these proteins are chemically altered, they detach from the cytoskeleton and stick together. (
  • The medical records were searched for incidence of dementia, Alzheimer's, or the progression of current dementia during the four-year period. (
  • The progression of the disease was measured in those that had a dementia diagnosis in 2002. (
  • The trial of nearly 2000 patients with late-onset Alzheimer's and Huntington's diseases shows that when applied to in vivo blood samples at baseline, the algorithm significantly predicted clinical deterioration and conversion to advanced disease stages. (
  • Clinical trials for Parkinson's disease have long relied on observing whether a therapy improves patients' symptoms, but such studies reveal little about how the treatment affects the underlying progressive neurodegeneration. (
  • This multicenter clinical study will investigate biomarkers of periodontal disease progression. (
  • Following periodontal therapy, subjects with periodontal disease will be followed for a maintenance period of 6 months for clinical and biological monitoring. (
  • By only injecting low concentrations of structurally-defined alpha synuclein aggregates into single dopaminergic neurons we can characterise early changes in neuronal function, which may occur before the clinical onset of the disease. (
  • Hypertensive heart disease is a constellation of abnormalities that includes left ventricular hypertrophy (LVH), systolic and diastolic dysfunction, and their clinical manifestations including arrhythmias and symptomatic heart failure. (
  • Therapeutic targeting of this terminal C5-C5a receptor axis with selective antagonists, or C5 inhibitory molecules, could therefore still be potential clinical candidates to slow disease progression in ALS. (
  • A group of younger onset patients with a typical long duration clinical course of Parkinson's disease. (
  • These cases with higher loads of Lewy bodies and shorter survivals suggest that widespread Lewy body pathology either occurs at the onset of clinical disease or rapidly infiltrates the brain. (
  • A landmark clinical study in the Lancet provides convincing evidence that a frequently overlooked therapy for genetically-caused emphysema is effective and slows the progression of lung disease. (
  • The overall goal is to improve understanding on how to stop neurons from degenerating and stop clinical progression. (
  • A two year clinical and imaging follow up from the initial recruitment will allow to define whether the combined measurements can be used by clinical neurologists to define the disease course and better identify therapeutic options for patients. (
  • The investigators found that clinical markers (functional status, the number of joints involved, joint pain and swelling) did not help in predicting disease progression. (
  • This will support the development of new evidence-based treatments in Europe through deeper disease understanding, better patient stratification for clinical trials, and improved accuracy of diagnosis and prognosis. (
  • Clinical trials repeatedly fail because disease heterogeneity prevents bulk response. (
  • The models are fundamentally new avenues for understanding the complexity of clinical phenotypes in multifactorial neurological diseases. (
  • SYDNEY & AUCKLAND, New Zealand--( BUSINESS WIRE )--130 weeks after treatment all four patients who took part in Living Cell Technologies Limited's Phase I/IIa clinical study of NTCELL ® for Parkinson's disease remain well and there are no safety concerns. (
  • This approach may be incorporated into clinical trials to assess disease-modifying agents. (
  • Ultimately, 30 biomarkers showed significant associations with rapid progression and adjusted for clinical characteristics. (
  • The most recent study , published in the Journal of Parkinson's Disease, looked at data from a clinical trial that was done to determine whether creatine could be disease-modifying. (
  • Several therapies are in clinical testing for disease modification. (
  • Isradipine (a blood pressure medication) and inosine (a supplement that raises urate, an antioxidant) are in Phase III clinical trial testing to determine whether they could slow or stop the progression of Parkinson's. (
  • While the established clinical outcome measures largely rely on physiological and functional tests, MSOT imaging can be an objective modality to quantify the amount of muscular fibrosis, thereby potentially providing a non-invasive and more objective measurement of disease progression and treatment response. (
  • For most diseases with short incubation periods (e.g., the common cold), treatment does not intervene until disease symptoms appear, but the very long incubation period of HIV infection allows time to treat the infection prior to the appearance of clinical disease. (
  • The ACCORD Eye Study clearly indicates that intensive glycemic control and fibrate treatment added to statin therapy separately reduce the progression of diabetic retinopathy," said Emily Chew, M.D., chair of the Eye Study and chief of the Clinical Trials Branch of the Division of Epidemiology and Clinical Applications at the National Eye Institute (NEI). (
  • Source: Clinical Nutrition, October 2014 Research: Dyslipidemia is a risk factor for cardiovascular disease that has become an increasing public health problem. (
  • Melissa Houser, MD, is the clinical director of the Parkinson's Disease and Movement Disorder Center at Scripps Clinic in San Diego. (
  • Following infection with HIV-1, the rate of clinical disease progression varies between individuals. (
  • In some cohorts, individuals who experience signs of progression, but whose clinical and laboratory parameters remain stable over long periods of time, are classified as Long Term Survivors (LTS). (
  • A new study shows that activity declines over time in different brain areas for people with Parkinson's disease and 2 related syndromes. (
  • Parkinson's disease destroys neurons in the brain that are essential for controlling movement. (
  • Other disorders can cause symptoms similar to those of Parkinson's disease. (
  • When people don't show all of the classic symptoms of Parkinson's disease, or have additional symptoms, they're said to have "parkinsonism. (
  • The team enrolled 46 patients with Parkinson's disease, 13 with MSA, 19 with PSP, and 34 healthy controls. (
  • For decades, the field has been searching for an effective biomarker for Parkinson's disease," says Dr. Debra Babcock, a neuroscientist and neurologist at NINDS. (
  • This study is an example of how brain imaging biomarkers can be used to monitor the progression of Parkinson's disease and other neurological disorders. (
  • In experiments performed with cultures of human brain cells and live mouse models, they report the drug blocked the degradation of brain cells that is the hallmark of Parkinson's disease. (
  • They found that microglia, a brain cell type that sends signals throughout the central nervous system in response to infection or injury, had the most sites for NLY01 to bind to-two times higher than the other cell types, and 10 times higher in humans with Parkinson's disease compared to humans without the disease. (
  • The activated astrocytes we focused on go into a revolt against the brain," says Dawson, "and this structural breakdown contributes to the dead zones of brain tissue found in those with Parkinson's disease. (
  • The ideas was that if we could find a way to calm those astrocytes, we might be able to slow the progression of Parkinson's disease. (
  • They explored this hypothesis by testing the drug's effectiveness in mice engineered to have a rodent version of Parkinson's disease. (
  • In one experiment, Dawson's team injected the mice with alpha-synuclein, the protein known to be the primary driver of Parkinson's disease, and treatedmice with NLY01. (
  • However, Dawson's team found that the mice treated with NLY01 maintained normal physical function and had no loss of dopamine neurons, indicating that the drug protected against the development of Parkinson's disease. (
  • In a second experiment, Dawson's team used mice that were genetically engineered to naturally produce more human-type alpha-synuclein typically used to model human Parkinson's disease that runs in families. (
  • Upon further investigation, Dawson's team found that the brains of the mice treated with NLY01 showed few signs of the neurodegenerative characteristics of Parkinson's disease. (
  • Parkinson's disease is a progressive disorder of the nervous system that affects approximately 1 million people in the U.S., according to the Parkinson's Foundation . (
  • The rich and longitudinal (gathered over time) dataset available through the Parkinson's Progression Markers Initiative provides a unique opportunity to gain insights into the progression of Parkinson's disease. (
  • A hallmark of Parkinson's disease is the degeneration of a group of dopaminergic neurons in the brain, which play key roles in movement initiation and co-ordination. (
  • It is known that patients treated for type two diabetes have less prevalence of Parkinson's disease. (
  • The present study describes the pathological progression of longitudinally followed cases with levodopa-responsive Parkinson's disease who came to autopsy during the Sydney Multicenter Study of Parkinson's disease. (
  • Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. (
  • Braak H, Rub U, Del Tredici K (2006) Cognitive decline correlates with neuropathological stage in Parkinson's disease. (
  • Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. (
  • Hely MA, Morris JG, Rail D, Reid WG, O'Sullivan DJ, Williamson PM, Genge S, Broe GA (1989) The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. (
  • Patients recently diagnosed with Parkinson's disease that have low levels of vitamin B12 develop symptoms faster than those with higher levels, suggesting supplementation could postpone the progression of symptoms, new research has found. (
  • Disease progression in patients with improved vitamin B12 levels was found to be much slower with them exhibiting a decreased score on the Unified Parkinson's Disease Rating Scale (UPDRS) (a measure of Parkinson's disability) compared with those maintaining low levels of the vitamin. (
  • A deficiency of this essential vitamin promotes the development of neurological and motor symptoms associated with Parkinson's disease, including depression, paranoia, muscular numbness and weakness. (
  • According to the Parkinson's Disease Foudnation, approximately 1 million people have Parkinson's disease in the United States. (
  • Addressing Parkinson's disease symptoms, genetics, treatment options and more from NorthShore neurologist-Ashvini Premkumar, MD- discuss and raise awareness about this common and often disabling neurological disorder. (
  • There is no established method of detecting Parkinson's disease before symptoms begin. (
  • Because patients with Parkinson's disease may lose their sense of smell decades before the onset of their movement disorder, some investigators have explored the use of smell testing as a method of detecting Parkinson's disease in at-risk subjects (e.g., persons who carry a rare gene mutation known to cause Parkinson's disease). (
  • We are currently conducting a study at NorthShore to determine if persons with mild to moderate traumatic brain injury, who are at an 11-fold increased risk for Parkinson's disease, have lower DATSCAN binding than persons without a history of brain injury. (
  • This study would demonstrate that it's possible to detect Parkinson's disease in at-risk subjects before symptoms begin. (
  • DATSCAN could prove useful as a method to develop asymptomatic Parkinson's disease in at-risk subjects who could then be prescribed treatments or lifestyle changes that might delay or possibly even prevent the onset of Parkinson's disease symptoms. (
  • My research associate Dr. Ying Wu is also exploring the use of automated MRI brain measurements in the same brain injury population to see whether MRI may prove effective in detecting preclinical Parkinson's disease changes in at-risk subjects. (
  • My research collaborators and I have conducted several studies of gender differences in Parkinson's disease. (
  • At every age men are 1.5 times more likely to develop Parkinson's disease than women. (
  • We observed no convincing difference in survival for men and women with Parkinson's disease. (
  • My collaborators and I observed no important differences in the rates of Parkinson's disease worldwide, and I'm not aware of any convincing data to suggest that symptoms of Parkinson's disease or its outcomes differ according to race or ethnicity. (
  • What are some of the later complications of Parkinson's disease? (
  • Typically we associate Parkinson's disease with movement disorders. (
  • Parkinson's disease is not just a movement disorder though. (
  • There is no proven method of slowing or halting the progression of Parkinson's disease. (
  • In all patients NTCELL treatment continues to show improvement over baseline, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS). (
  • This study will confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson's disease patient sub-group. (
  • Our goal, subject to continued satisfactory data, remains to obtain provisional consent and launch NTCELL as the first disease modifying treatment for Parkinson's disease in 2018," says Dr Taylor. (
  • To receive news and publication updates for Parkinson's Disease, enter your email address in the box below. (
  • MRI Correlates of Parkinson's Disease Progression: A Voxel Based Morphometry Study," Parkinson's Disease , vol. 2015, Article ID 378032, 8 pages, 2015. (
  • A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer's disease, epilepsy, Parkinson's disease, and multiple sclerosis. (
  • Could MAO-B Inhibitors Slow Parkinson's Disease Progression? (
  • They may be taken alone to treat mild symptoms in earlier stages of Parkinson's disease (PD) or coupled with other medications (such as levodopa or dopamine agonists) to treat more moderate symptoms in middle or later phases of Parkinson's. (
  • The goal of this study is to describe modifiable lifestyle variables associated with reduced rate of Parkinson's disease (PD) progression. (
  • Mischley LK, Lau RC, Bennett RD. Role of Diet and Nutritional Supplements in Parkinson's Disease Progression. (
  • TY - JOUR T1 - Role of Diet and Nutritional Supplements in Parkinson's Disease Progression. (
  • What Is the Typical Progression of Parkinson's Disease? (
  • Video / HealthMakers / Melissa Houser, MD / What Is the Typical Progression of Parkinson's Disease? (
  • If I have Alzheimer's, Will I Also Get Parkinson's Disease? (
  • She discusses research into causes and treatment of Parkinson's disease, including stem cell research. (
  • The epidemiology of HIV disease progression has attempted to characterize the distribution of possible lengths of the incubation period and the AIDS survival period, to identify laboratory tests useful for prognosis and treatment decisions, and to determine what cofactors accelerate or retard the rate of disease progression. (
  • The network was used to measure the rate of disease progression in the study participants. (
  • A novel machine-learning algorithm that uses genetic data from patient blood samples can significantly predict and explain the progression of neurodegenerative diseases such as Alzheimer's and Huntington's. (
  • That's very important because there has been a lot of emphasis on finding brain biomarkers of neurodegenerative diseases like Alzheimer's. (
  • The test measures the neurofilament light chain (neurofilament), a protein released from damaged brain cells, which has been linked to other neurodegenerative diseases but hasn't been studied in the blood of Huntington's disease (HD) patients before. (
  • Much of that work has centered on misfolded proteins, which are known to be key culprits in HD and several other neurodegenerative diseases. (
  • Dr. Sudha Seshadri, director of the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases at UT Health San Antonio, said the medical field is increasingly recognizing the role of daily health information in getting "a complete picture at all stages of when a person is well and at risk for different diseases. (
  • An international research team led by the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn comes to this conclusion in the journal Nature . (
  • The current study led by Prof. Michael Heneka, director of the Department of Neurodegenerative Diseases and Gerontopsychiatry at the University of Bonn and a senior researcher at the DZNE, provides new insights into why tau proteins are transformed. (
  • It appears that inflammatory processes mediated by the inflammasome are of central importance for most, if not all, neurodegenerative diseases with tau pathology. (
  • 1 ) recently demonstrated that superoxide dismutase 1 (SOD1) transgenic mice deficient in complement components C1q and C3 do not have extended survival, concluding that global complement activation does not affect overall disease in amyotrophic lateral sclerosis (ALS). (
  • A team of biomedical scientists has identified a molecule that targets a gene known to play a critical role in the rapid progression of amyotrophic lateral sclerosis (ALS), sometimes known as Lou Gehrig's disease, the neurodegenerative disease that affects motor neurons - nerve cells in the brain and spinal cord that link the nervous system to the voluntary muscles of the body. (
  • A regression analysis revealed that individuals with a history of cardiovascular disease had a significantly higher risk of rapid progression (OR 2.33) despite having lower baseline IOP. (
  • This study identifies cardiovascular disease as a major risk factor for rapid progression of glaucoma, despite lower baseline IOPs. (
  • Rapid progression was originally thought to be continent specific, as some studies reported that disease progression is more rapid in Africa, but others have contested this view. (
  • During the initial weeks after HIV infection, qualitative differences in the cell-mediated immune response are observed that correlate with different disease progression rates (i.e., rapid progression to WHO stage 4 and the rapid loss of CD4+ T cell levels versus normal to slow progression to WHO stage 4 and the maintenance of CD4+ T cell counts above 500/µl). (
  • We don't have good biomarkers for neurodegenerative disease," he said. (
  • This study suggests measurable targets, called biomarkers, which could be useful for assessing whether a drug slows or even stops the progression of the disease in the brain. (
  • We have been trying to identify blood biomarkers to help track the progression of HD for well over a decade, and this is the best candidate that we have seen so far. (
  • Statistical analyses will compare biomarkers and microbial species between periodontally healthy subjects and subjects with periodontal disease, between progressing and non-progressing periodontally diseased sites, and between periodontally diseased sites before and after periodontal therapy. (
  • Thus we identified several novel associations of biomarkers with CKD progression and the utility of a small panel of biomarkers to improve prediction. (
  • 2007) Human exhaled air analytics: biomarkers of diseases. (
  • Together, our findings primarily implicate hypoxia, oxidative stress, as well as membrane lipid remodeling in progression to AD. (
  • We will create a robust assessment score after tuning the models for the specific disease findings. (
  • We are excited to have these new insights into how amyloid plaque formation influences iron chemistry in the human brain, as our findings coincide with efforts by others to treat Alzheimer's disease with iron-modifying drugs. (
  • These human tumor findings suggest that patients whose prostate tumor is surrounded by a stroma with decreased levels of the Cav-1 protein may have an overall worse prognosis and a higher chance of disease relapse. (
  • Our findings strongly suggest that a person's gender, cognitive state and amount of lesions on the brain are important factors for predicting MS progression," said study author Maria Pia Amato, MD, with the University of Florence in Italy. (
  • The findings, scientists indicate, are some of the most compelling ever produced in the search for a therapy for ALS, a debilitating and fatal disease, and were just published in Neurobiology of Disease . (
  • The findings, published in a recent issue of the Journal of Neuroscience, provide insight in determining the feasibility of biosynthetic polyphenols as a possible therapy for AD in humans, a progressive neurodegenerative disease for which there is currently no cure. (
  • The findings make it possible to evaluate the effects of new drugs on disease progression before symptoms actually appear. (
  • The Centers for Disease Control and Prevention (CDC) has released findings that genes influence susceptibility to HIV infection and progression to AIDS. (
  • The investigators used data from 1969 patients with late-onset Alzheimer's and Huntington's disease from three large-scale databases, each of which was processed and analyzed independently. (
  • The first blood test that can predict the onset and progression of Huntington's disease has been identified by a UCL-led study. (
  • In the group who had no symptoms at the start of the study, the level of neurofilament predicted subsequent disease onset, as volunteers with high neurofilament levels in the blood at the start were more likely to develop symptoms in the following three years. (
  • After taking into account factors already known to predict progression - age and a genetic marker - the blood level of neurofilament was still able to independently predict onset, progression and the rate of brain shrinkage as measured by MRI scans. (
  • The radiologist has an invaluable role in this process, as imaging provides direct insight into the various factors and treatments that delay or accelerate disease onset. (
  • The last group had an older onset, shorter survival, and a more complex disease course with higher Lewy body loads and a higher proportion with additional neuropathologies. (
  • Cruchaga and colleagues followed this up by looking for a connection between this SNP and disease parameters such as risk, age of onset, and rate of progression. (
  • In the long term, we aim to prevent the onset of symptoms of the diseases and the progression of severity by highly individualized optimization by developing personalized scientific intervention measures from PHR (Personal Health Record)/EMR (Electronic Medical Record). (
  • By current definition, people with benign MS are those who remain "fully functional" after 15 or more years from disease onset. (
  • CDAA-fed rats develop early-onset progressive NASH, which offers the opportunity to probe anti-NASH compounds with potential disease-modifying properties. (
  • Most people with Huntington's disease develop signs and symptoms in their 40s or 50s, but the onset of disease may be earlier or later in life. (
  • Having a better way to track the disease at its earliest stages will make it easier to test drugs designed to delay or even prevent the onset of symptoms. (
  • Thus, effective disease assessment at early stages is essential in order to improve diagnosis and prognosis and to provide prompt treatment before the onset of end-stage renal disease. (
  • Part 4 describes disease symptoms and outcomes in tanoak, Notholithocarpus (=Lithocarpus) densiflorus. (
  • They found that levels of the brain protein were increased throughout the course of HD - even in carriers of the HD genetic mutation who were many years from showing symptoms of the disease. (
  • When compared with placebo and other drugs, long-term use of finasteride improves urinary tract symptoms associated with benign prostatic hyperplasia, and reduces disease progression. (
  • The inherent complexity of neurological disease, the overlap of symptoms and pathologies, and the high comorbidity rate suggests a systems medicine approach, which matches the specific challenge of this call. (
  • These mice developed very severe symptoms of Huntington's disease," said La Spada. (
  • However, people with benign MS occasionally develop renewed disease activity or progression, and can experience severe symptoms. (
  • A new study proposes that MAO-B inhibitors -- drugs used to treat Parkinson's motor symptoms -- may slow disease progression when taken for longer periods of time. (
  • Medications are available to help manage the symptoms of Huntington's disease, but treatments do not prevent the physical, mental and behavioral decline associated with the condition. (
  • Genetic testing for Huntington's disease can be performed to determine whether a person carries the gene and is developing the disease even before symptoms appear. (
  • Even though a carrier of the Huntington's disease gene may not have experienced symptoms, changes in the brain have already taken place, which ultimately lead to severe disability. (
  • Below is a list of common medications used to treat or reduce the symptoms of treatment+to+slow+progression+of+coronary+artery+disease. (
  • You need someone who will keep up with the varying symptoms of this multi-faceted disease. (
  • What are the stages of Alzheimer's disease? (
  • Although every person with Alzheimer's experiences the disease differently, it is possible to divide its typical progression into a series of stages. (
  • Looking at Alzheimer's disease in stages can provide a clearer idea of the possible changes that could affect someone following their diagnosis. (
  • Some people think of the disease as having seven stages, while others refer to just three. (
  • In this study we show that D1R/H3R complexes are found within the brain at early- but not late-disease stages and that targeting these complexes could potentially slow the progression of early-stage diseases. (
  • Kaplan-Meier plot of ages (in days) in which SOD1 G93A mice with normal (CD88 +/+ , orange line) or fully deleted (CD88 −/− , blue line) CD88 reached end-stage of disease (complete hindlimb paralysis and an inability to right itself once placed on its back) in males ( A ) and females ( B ). Average (±SEM) ages of the disease end stages are also shown. (
  • This fact sheet will discuss the various stages of hepatitis C disease progression. (
  • Studies find Namenda can also slow mental decline when used either alone or in combination with Aricept, and it seems to work even in people in the moderate to severe stages of the disease. (
  • Having this ability provides an opportunity for scientists to study how the disease first develops and how it progresses in its early, presymptomatic stages. (
  • Micronutrient supplementation may be effective when started in the early stages of HIV disease. (
  • This is the first time a potential blood biomarker has been identified to track Huntington's disease so strongly," study's senior author, Dr Edward Wild (UCL Institute of Neurology). (
  • We see this as a promising biomarker that affects a lot of key aspects of Alzheimer's disease," Swanson said. (
  • Results demonstrate that MSOT can visualize and quantify the distribution and concentration of collagen as a measure for degenerated muscular tissue, demonstrating a biomarker for DMD disease progression. (
  • Spectroscopic analysis allows to quantify collagen content which is a disease biomarker in DMD. (
  • Saa3 is released in high amounts during inflammation or injury so it is a useful biomarker of the disease. (
  • We sought to determine the serum metabolomic profiles associated with progression to and diagnosis of AD in a prospective study. (
  • Finally, there were no structural measurements reported such as cup-to-disc ratio or retinal nerve fiber layer measurements that could corroborate glaucoma progression diagnosis. (
  • Part of our challenge in making the diagnosis is understanding the correlation between both tests, which is also especially important for progression. (
  • Gender and brain lesions may also determine the risk of progression of MS years after diagnosis. (
  • This suggests that providers should pay closer attention to weight at diagnosis to predict the response to treatment and disease trajectory. (
  • These drugs work best when prescribed early in the disease (which is why early diagnosis is so important). (
  • PET scan helps in the diagnosis of conditions like cancer, heart disease and brain disorders. (
  • Although significant progress has been made in terms of treatment options for MS, new technologies and a more comprehensive understanding of the disease has fuelled new consensus statements from clinicians, focusing on the importance of early diagnosis and referral to specialists, access to newer disease modifying therapies sooner after diagnosis, rapid and efficient decision making when switching medications and the importance of lifestyle changes to support brain health. (
  • We are shocked at how well this treatment can stop the progression of ALS," said Joseph Beckman, lead author on this study, a distinguished professor of biochemistry and biophysics in the College of Science at Oregon State University, and principal investigator and holder of the Burgess and Elizabeth Jamieson Chair in OSU's Linus Pauling Institute. (
  • The first ever drug which scientists believe could stop the progression of Alzheimer's disease will be unveiled later today. (
  • Photo (c) Shidlovski - Getty Images While early detection is key for consumers struggling with Huntington's disease, finding comprehensive therapies can be difficult. (
  • It was already well-known that dopamine signaling goes away in Huntington's disease, but we and other research teams have shown more recently that dopamine receptors and histamine receptors are found together and control signaling in the brain," said researcher David Moreno-Delgado. (
  • Because dopamine receptors are found in many normal cells throughout the central nervous system, we proposed that targeting dopamine signaling through the histamine receptor might be a more effective strategy to slow the progression of Huntington's disease. (
  • The imbalance of dopamine signalling in disease progression represents a potential 'point of no return' for Huntington's disease patients as it can eventually lead to nerve-cell dysfunction and death," said researcher Peter McCormick. (
  • The team, led by scientists at the UCL Huntington's Disease Centre working with colleagues in Sweden, the USA, Canada, France and the Netherlands, measured neurofilament levels in blood samples from the TRACK-HD study, an international project that followed 366 volunteers for three years. (
  • Neurofilament has the potential to serve as a speedometer in Huntington's disease, since a single blood test reflects how quickly the brain is changing. (
  • Dr Robert Pacifici, chief scientific officer of CHDI Foundation, a US non-profit Huntington's disease research foundation, welcomed the development. (
  • Huntington's disease is a fatal genetic neurological disease. (
  • Here we used a computational approach to identify a functional brain network associated with the progression of preclinical Huntington's disease (HD). (
  • Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. (
  • It improved motor function, reduced neurodegeneration and increased survival in a mouse model of Huntington's disease and reduced toxicity in neurons generated from human HD stem cells. (
  • A new way to measure the progression of Huntington's disease, using positron emission tomography (PET) to scan the brains of carriers of the gene was discovered by investigators. (
  • Huntington's disease causes the progressive breakdown of nerve cells in the brain, which leads to impairments in movement, thinking and emotions. (
  • Huntington's disease is an inherited disease, passed from parent to child through a mutation in the normal gene. (
  • Each child of a parent with Huntington's disease has a 50/50 chance of inheriting the Huntington's disease gene, and a child who inherits the gene will eventually develop the disease. (
  • Brain imaging is one tool that could be used to track how quickly Huntington's disease progresses in gene carriers. (
  • The Feinstein Institute investigators then confirmed the progression rate through independent measurements in scans from a separate group of Huntington's disease gene carriers who were studied in the Netherlands. (
  • The investigators believe that progression networks similar to the one identified in Huntington's disease carriers will have an important role in evaluating new drugs for degenerative brain disorders. (
  • Huntington's disease is an extremely debilitating disease. (
  • Avicena Group, Inc.announced the selection of the optimal dose of HD-02, its novel drug candidate for the treatment of Huntington's Disease. (
  • Can SGLT2 inhibitors really help these patients, too, and prevent them from reaching end stage kidney disease in need of regular dialysis treatments or renal transplantation? (
  • The primary outcome of worsening of kidney function was a composite of sustained ?50% eGFR decline, occurrence of end stage kidney disease, or renal or CV death. (
  • In an editorial that accompanied the study, Lee A. Hebert, M.D., of Ohio State University in Columbus wrote that ACE inhibitor therapy might stretch progression to renal failure from 3.5 years to seven years. (
  • Necrotizing crescentic glomerulonephritis (CGN) and focal segmental glomerulosclerosis (FSGS) are life-threatening diseases leading to irreversible renal failure. (
  • Doctors need to have full and frank discussions with patients about the potential risks and benefits of using direct-acting antivirals (DAAs) to treat hepatitis C in late-stage liver disease, especially among those waiting for a liver transplant, liver specialists said at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona. (
  • In periodontal disease, host recognition of bacterial constituents, including lipopolysaccharide (LPS), induces p38 MAPK activation and subsequent inflammatory cytokine expression, favoring osteoclastogenesis and increased net bone resorption in the local periodontal environment. (
  • In this paper, we discuss evidence that the p38/MAPK-activated protein kinase-2 (MK2) signaling axis is needed for periodontal disease progression: an orally administered p38 α inhibitor reduced the progression of experimental periodontal bone loss by reducing inflammation and cytokine expression. (
  • MAPK phosphatase-1 (MKP-1), a negative regulator of MAPK activation, was also critical for periodontal disease progression. (
  • Collectively, these studies highlight the importance of p38 MAPK signaling in immune cytokine production and periodontal disease progression. (
  • The primary study outcome will be progression of periodontal disease as determined by CAL. (
  • The study will enroll 375 subjects with periodontal disease and 125 periodontally healthy subjects. (
  • Subjects displaying periodontal disease progression greater than an established threshold will receive periodontal rescue therapy at progressing periodontal sites and continue with monitoring. (
  • Periodontally healthy subjects and non-progressing sites in subjects with periodontal disease will serve as controls. (
  • After 12 months, subjects with periodontal disease will receive periodontal therapy consisting of 4 quadrants of scaling and root planing. (
  • Subjects with periodontal disease will be enrolled. (
  • After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. (
  • He noted that "nephrologists have been using these drugs for 18 to 20 years to try to postpone the progression of kidney disease simply by extrapolating from data in the diabetic population. (
  • Reuters) - GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients. (
  • The method especially is used in assessing whether an RA patient is at risk of disease progression. (
  • 1. A method for aiding in assessing the risk of disease progression for a patient having rheumatoid arthritis (RA), the method comprising the steps of obtaining a liquid sample from the patient, measuring in said sample a concentration of C-reactive protein (CRP), a concentration of interleukin-6, and optionally a concentration of one or more additional markers, and correlating the concentrations measured to the risk of disease progression. (
  • We are always looking for novel targets or new insight into disease progression, remission or susceptibility,' Ward said. (
  • both of these diseases are also associated with systemic inflammation, similar to HIV infection. (
  • Our study demonstrates that dietary intake has a discernable impact on the natural history of HIV/SIV infections and suggests that dietary changes can be used as adjuvant approaches for HIV-infected subjects, to reduce inflammation and the risk of non-AIDS comorbidities and possibly other infectious diseases. (
  • This results in a decrease of inflammation, stabilization of the plaque and, therefore, obstruction of the progression of the disease. (
  • Inflammation drives the progression of neurodegenerative brain diseases and plays a major role in the accumulation of tau proteins within neurons. (
  • They had developed a mouse model where the mice were engineered with a light-emitting gene that glowed to help monitor inflammation in kidney disease progression. (
  • Alkali therapy, whether pharmacologically or through dietary intervention, appears to slow CKD progression, but an appropriately powered randomized controlled trial with a low risk of bias is required to reach a more definitive conclusion. (
  • The best we can do at this point is slow down the rate of progression. (
  • As new, personalized treatments are developed to slow disease progression, there is a vital need for imaging methods that can detect response to therapy at early follow-up times. (
  • It seemed that the medication could also slow progression of CKD. (
  • It was not until 2019 that the CREDENCE trial provided evidence that the SGLT2 inhibitor Canagliflozin could slow CKD progression in patients with T2D and CKD with albuminuria who were already on standard RAAS blockade and baseline glucose lowering therapy [3]. (
  • Is there a way to slow or halt the progression of PD? (
  • Do MAO-B Inhibitors Slow Parkinson's Progression? (
  • Today we have a number of medications that can slow the progression of the disease, and a vaccine under development. (
  • So if you're worried about developing Alzheimer's, or even if you've recently been diagnosed, taking steps to reduce your risk factors for heart disease can also reduce your risk of Alzheimer's and, quite possibly, slow the progression of the disease if you have it. (
  • Studies find they can slow the progression of the disease, freeing up caregivers and reducing their stress. (
  • Your doctor may prescribe you a blood pressure medication called an angiotensin converting enzyme (ACE) inhibitor (e.g., ramipril, perindopril) or an angiotensin receptor blocker (ARB, e.g., valsartan, losartan), as they slow the progression of kidney damage. (
  • Considering taking medication to treat treatment+to+slow+progression+of+coronary+artery+disease? (
  • Individuals with a broad expansion of the V-beta chain of the T cell receptor of CD8+ T cells during primo-infection appear to have low levels of virus six to twelve months later, which is predictive of relatively slow disease progression. (
  • 001). Lower iron content in the thalamus and high iron content in other deep gray matter structures of patients with MS were associated with longer disease duration, higher disability degree and disease progression. (
  • Finally, a team of scientists has developed a new concept called "motivational reserve," similar to "cognitive reserve," that may be related to incidence and progression of Alzheimer's. (
  • The results showed unique patterns of activity for each disease, suggesting ways to monitor their progression and treatment. (
  • Investigators in Asia and South America enrolled patients who had non-squamous stage IIIB/IV NSCLC and progression or relapse after first-line treatment with a platinum-based chemotherapy regimen. (
  • Treatment continued until progression, death, or development of unacceptable toxicity. (
  • How a prostate tumor communicates with its microenvironment, or stroma, is a vital process we need to understand to assess the aggressiveness of a patient's disease and potential response to treatment," said Dolores Di Vizio, MD, PhD, associate professor in the Urologic Oncology Research Program and senior investigator of the study. (
  • A patient at high risk of a rapidly progressing disease might be a patient in need for treatment or if already treated in need for a different and more effective treatment. (
  • 2. The method according to claim 1, wherein the patient is undergoing treatment with an anti-rheumatic drug selected from group consisting of disease modifying anti-rheumatoid drugs (DMARDs) when the assessment is performed. (
  • ZEISS supports complex disease management by integrating critical data points necessary to make accurate decisions on treatment paths and providing at-a-glance history and progression trends with interactive analysis. (
  • Purvesh Khatri and his colleagues have developed a new tool that can help determine the progression of scleroderma and how well a patient is responding to treatment. (
  • Because the measures of disease progression are imprecise, said Khatri, it can take two years for physicians to be sure if a given treatment is having any effect. (
  • Many efforts to find a treatment for Alzheimer disease have focused on discovering a way to reduce Aβ, with largely disappointing results so far. (
  • For now, the role of pharmaceuticals is not only providing such treatment but also "preventing disease" and "limiting the severity of disease" is becoming much more important. (
  • But if treatment was resumed, the mice gained weight, progression of the disease once again was stopped, and the mice lived another 6-12 months. (
  • They added: 'This is thought consistent with a treatment effect that changes the underlying pathology of Alzheimer's disease. (
  • In conclusion, the authors said, the results augment knowledge about the natural course of Stargardt disease, and they added that the fact that many eyes developed DDAF in less than 5 years suggests that the incidence of DDAF may be an appropriate outcome measure for treatment trials. (
  • The incubation period of an infectious disease characterizes the natural history from infection to initial manifestations of the disease in the absence of treatment. (
  • My team, along with many members of the scientific community, did not know how we could harness the efficacy of naturally occurring polyphenols in food for treatment of Alzheimer's disease," Dr. Pasinetti said. (
  • I look forward to further studying this compound to determine its feasibility as a treatment for Alzheimer's disease. (
  • Hepatitis C virus (HCV) treatment-when successful-offers survival benefits over and above reductions in liver disease among people coinfected with both HIV and HCV, according to a study reported February 19 at the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. (
  • When HCV treatment is successful, it greatly reduces the risk of liver disease progression and liver-related deaths. (
  • Expanding the knowledge of factors involved in the development and progression of hepatic steatosis and NAFLD is mandatory in order to enhance the repertoire of tools for assessing disease severity and optimizing treatment. (
  • This review provides evidence that Prostate cancer initiation and progression is promoted by cow´s milk by hyperactivated mTORC1 signaling. (
  • To further understand the systemic and ocular risk factors for rapid glaucoma progression, investigators examined a cohort of rapid and nonrapid disease progressors. (
  • The rate of metabolic network progression in this cohort was compared with the corresponding estimate obtained in a separate group of 21 premanifest HD carriers who were scanned twice over a 2-year period. (
  • He concluded that there did appear to be real differences in HIV disease progression if a person achieved an SVR, but that further studies-along with more data from the GESIDA cohort-will be necessary to determine the size of the effect. (
  • Kidney disease can be caused by and involved in other complex diseases such as diabetes and cardiovascular disease. (
  • There is no known cause, but some risk factors have been identified, such as increasing age, family history, smoking, and history of cardiovascular disease. (
  • Research, published today in the journal Neurology , describes how mutations in a specific gene that codes for a neural growth factor appear to predict how quickly memory loss will progress in people with Alzheimer's disease. (
  • In people with Alzheimer's disease, this protein clumps together and forms plaques. (
  • The brains of people with Alzheimer's disease have two distinct hallmarks. (
  • The participants in the study were relatively young for people with Alzheimer's disease: 63% were under the age of 65 when they enrolled. (
  • Cruciferous vegetable consumption was strongly associated with reduced risk of prostate cancer progression. (
  • Cholesterol has been shown to be a driver of prostate cancer progression," said Di Vizio. (
  • EuroPOND will develop a data-driven statistical and computational modeling framework for neurological disease progression. (
  • EuroPOND will develop uniquely powerful data-driven statistical-and-computational models of neurological disease progression. (
  • Conversely, he found that elevating levels of PGC-1 alpha in HD mice virtually eliminated the misfolded proteins and rescued neurological disease and neurodegeneration in the HD mice. (
  • kidney disease progression. (
  • Retrieved on July 08, 2020 from (
  • and iron supplementation was associated with faster progression (P = 0.022). (
  • The higher the viral load set point, and the lower the CD4 set point, the faster the person's progression. (
  • The team used publicly available patient data shared by hospitals across the United States to search for a set of genes whose activity would mark the progression of systemic sclerosis, or SSc. (
  • Newswise - Cognitive testing may help people with inactive or benign multiple sclerosis (MS) better predict their future with the disease, according to a study published in the July 29, 2009, online issue of Neurology ®, the medical journal of the American Academy of Neurology. (
  • A recent study published in Radiology found that evaluating the differences in iron accumulation in the deep gray matter of the brain using a magnetic resonance imaging (MRI) technique may help to identify patients with multiple sclerosis (MS) that are at greater risk for disease progression and disability. (
  • So a second aim of the study was to see if we can take a minimally invasive test such as a blood test and use it to give us an idea about which stage of disease patients are at, or how close they are to developing a particular disorder. (
  • The study included 32 people with early-stage Alzheimer's disease. (
  • Progression of non-small cell lung cancer slowed by almost half when pemetrexed (Alimta) and erlotinib (Tarceva) were used in combination instead of monotherapy, a study found. (
  • VIENNA -- Progression of non-squamous non-small cell lung cancer (NSCLC) among never- and former light-smoker patients slowed by almost half when pemetrexed (Alimta) and erlotinib (Tarceva) were used in combination instead of monotherapy, a randomized study showed. (
  • FRIDAY, Nov. 14, 2014 (HealthDay News) -- Kidney disease may progress faster for diabetics who have kidney disease and also suffer from sleep apnea , according to a new study. (
  • Their study involved 56 people who had diabetes and kidney disease . (
  • The study, published in the Journal of Pathology, found that a decreased level of the Cav-1 protein in the stroma indicated tumor progression - a function opposite to the known role of Cav-1 within a tumor. (
  • The study, based on work done by Doris Germain of Mt. Sinai Hospital, found that the combination of the drugs bortezomib and fulvestrant -- versus fulvestrant alone -- doubled the rate of survival at 12 months and reduced the chance of cancer progression overall. (
  • Because the study showed a statistically significant benefit among patients whose disease progressed on an aromatase inhibitor, a larger phase III study comparing this combination to other approved therapies used after initial therapies fail, like exemestane and everolimus, should be done. (
  • At the beginning of the study, 86 participants had normal brain function, 135 expressed mild cognitive impairment (the precursor to Alzheimer's), and 64 had Alzheimer's disease. (
  • The study is available as open access in Neurobiology of Disease . (
  • This new information certainly raises interest in further study of MAO-B inhibitors as a disease-modifying therapies. (
  • One major study published in the New England Journal of Medicine gave 341 people with moderately severe Alzheimer's disease either Cognex (tacrine)-an older drug rarely used these days-vitamin E, the drug plus the vitamin, or a placebo for two years. (
  • A translational study conducted at the University Hospital Erlangen and published in Nature Medicine demonstrates that Multispectral Optoacoustic Tomography (MSOT), an imaging technology developed by the Munich-based company iThera Medical, can be used to visualize and quantify changes in tissue composition associated with the progression of the rare muscle disease Duchenne Muscular Dystrophy (DMD). (
  • None of these modifiers has been identified by conducting a genome-wide association study (GWAS), due to the low prevalence of the disease, which precluded the design of a properly powered discovery study. (
  • Dr. Giulio Maria Pasinetti is a named inventor of a pending patent application filed by Mount Sinai School of Medicine (MSSM) related to the study of Alzheimer's disease. (
  • New research has identified potential targets to inhibit the progression of liver disease and prevent cancer, according to a study published in Science Immunology . (
  • For the study, scientists from the liver immunology research unit of the University of Montreal Hospital Research Center evaluated the contribution of the type 3 cytokines interleukin (IL)-17A and IL-22 to the progression of liver fibrosis. (
  • This study aimed to be of use to policymakers and others interested in understanding the current status of the evidence around the wider costs to society of the progression of MS. (
  • The study found that people who took angiotensin receptor blockers were less likely to develop Alzheimer's and had slower rates of progression. (
  • The project will devise and implement, as open-source software tools, advanced statistical and computational techniques for reconstructing long-term temporal evolution of disease markers from cross-sectional or short-term longitudinal data. (
  • This paper describes several new longitudinal stochastic models, discusses factors that may affect their successful use in the modeling of disease progression, and illustrates one model, the Mixed Markov model, in connection with the progression of Alzheimer's disease. (
  • The project seeks to predict the progression of neurodegenerative disease. (
  • The research, called the Quantu Project, seeks to predict the progression of neurodegenerative disease by tracking individuals' day-to-day behaviors and physiological indicators. (
  • Understanding how the disease progresses in different patient cohorts may eventually inform more personalized treatments and, hopefully, improve quality of life and outcomes. (
  • No disease modifying treatments are yet available. (
  • This finding supports the idea that tau increases the severity of the disease, and implies that treatments targeting tau might delay disease progression. (
  • This fact sheet will discuss the Kidneys - the functions, diseases, treatments and how to keep these small but important organs healthy. (
  • This, in turn, not only slows progression of the disease, but also buys you time to benefit from new treatments that may be just around the corner. (
  • Parts 1 through 3 describe different disease outcomes that occur in coast live oak, Quercus agrifolia. (
  • There is widespread agreement that LVH is an important intermediate phenotype in the progression of hypertensive heart disease 1 and is associated with adverse outcomes. (
  • Multivitamins plus selenium in a single supplement, vs placebo, also reduced the risk of secondary events of combined outcomes for disease progression. (
  • Patients who received the combination as second-line therapy had a median progression-free survival (PFS) of 7.4 months as compared with 3.8 months with erlotinib alone and 4.4 months with pemetrexed monotherapy, according to a report here at the European Society for Medical Oncology. (
  • Systemic sclerosis, also called scleroderma, is an autoimmune disease that causes scarlike thickening of the skin and internal organs, such as the kidneys and lungs. (
  • 3. What is the general progression of Systemic Sclerosis withCREST varient? (
  • The research team propose that interactions between iron and amyloid that produce the chemically reduced iron species, including magnetite, may account for toxicity that contributes to the development and progression of Alzheimer's. (
  • Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. (
  • The goal, she said, is to identify how daily behavior correlates with neurodegenerative disease and its progression in the body. (
  • Understanding the significance of these metals to the progression of Alzheimer's could lead to more effective future therapies which combat the disease at its root. (
  • The evaluation of effective disease-modifying therapies for neurodegenerative disorders relies on objective and accurate measures of progression in at-risk individuals. (
  • There is a marked need for improved animal models of nonalcoholic steatohepatitis (NASH) to facilitate the development of more efficacious drug therapies for the disease. (
  • Christian Wiest, CEO at iThera Medical comments: 'We are excited to see that MSOT can potentially aid DMD patients suffering from this severe disease. (
  • HIV disease is a continuum of progressive damage to the immune system from the time of infection to the manifestation of severe immunologic damage by opportunistic infections (OI), neoplasms, wasting, or low CD4 lymphocyte count that define AIDS. (
  • Under normal conditions, these so-called transgenic mice will succumb to the disease in 387 days. (
  • In the brains of mice with Alzheimer's disease, decreased levels of JIP3 (right) induce the formation of larger amyloid plaques (red) and increased numbers of swollen axons filled with lysosomes. (
  • Acosta-Alvear expressed that although the results in mice are promising, it is important to remember that it is not a miracle drug that will prevent the disease. (
  • In order to identify novel markers of cells participating to destructive processes in extracapillary glomerular diseases, we carried out comparative analyses of RNA sequencing data from freshly isolated glomeruli from mice with a time course after nephrotoxic serum (NTS)-induced CGN at day 4 and day 10 (Fig. 1a ). (
  • A high-adenine diet composed of α-cornstarch, casein, sucrose, corn oil, cellulose, mineral mixture, vitamin mixture, L-cystine and adenine (0.2% w/w) were fed to the mice to induce kidney disease. (
  • The effectiveness of combination antiretroviral therapy that includes a protease inhibitor in slowing HIV disease progression appears to be altering the disease course significantly. (
  • Subsequent disease progression will be similarly defined except that the loss in CAL will be compared with the last visit at which disease progression was detected. (
  • If viral and CD4 set points are contingent on the virus levels of the person from whom HIV is acquired, this could influence the set points and the subsequent speed of disease progression. (
  • The CDAA diet led to marked hepatomegaly and fibrosis already after 4 weeks of feeding, with further progression of collagen deposition and fibrogenesis-associated gene expression during the 12-week feeding period. (
  • Pharmacological intervention with elafibranor, but not OCA, significantly reduced steatohepatitis scores, and fibrosis-associated gene expression, however, was unable to prevent progression in fibrosis scores. (
  • Advanced fibrosis can blunt the maintenance and recovery of CD4 cell counts, which might in turn affect the rate of progression to AIDS or death. (